Advertisement

Suppressor Cells and Malignancy

I. Suppressor Macrophages and Suppressor T Cells in Experimental Animals
  • David Naor
  • Jonathan S. Duke-Cohan
Part of the Advances in Immunity and Cancer Therapy book series (IMMUNITY, volume 2)

Abstract

“Suppressor Cells: Permitters and Promoters of Malignancy?” was the title of a review article published by one of us in 1979 (1). This paper focused on the interrelationships between a neoplasm and the cells regulating the immune system. Unfortunately, the question mark, which was an integral part of the title six years ago, cannot yet be replaced by an exclamation mark, because the mechanisms controlling tumor growth are still unclear. However, the intriguing hypothesis that suppressor cells support tumor growth, and that their elimination may encourage tumor rejection still occupies the imagination of many tumor immunologists who are using a variety of experimental model systems, both in animals and in humans, in order to test the above prediction.

Keywords

Spleen Cell Migration Inhibition Factor Suppressor Cell Mixed Lymphocyte Culture Delay Type Hypersensitivity Response 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Naor D: Suppressor cells: permitters and promoters of malignancy? Adv Cancer Res 29: 45–125, 1979.PubMedGoogle Scholar
  2. 2.
    Tada T, Okumura K: The role of antigen-specific T cell factors in the immune response. Adv Immunol 28: 1–87, 1979.PubMedGoogle Scholar
  3. 3.
    Unanue ER: The regulatory role of macrophages in antigenic stimulation, Part 2: Symbiotic relationship between lymphocytes and macrophages. Adv Immunol 31: 1–136, 1981.PubMedGoogle Scholar
  4. 4.
    Green DR, Flood PM, Gershon RK: Immunoregulatory T-cell pathways. Annu Rev Immunol 1: 439–463, 1983.PubMedGoogle Scholar
  5. 5.
    Dorf ME, Benacerraf B: Suppressor cells and immunoregulation. Annu Rev Immunol 2: 127–158, 1984.PubMedGoogle Scholar
  6. 6.
    Schatten S, Granstein RD, Drebin JA, Greene MI: Suppressor T-cells and the immune response to tumors. CRC Crit Rev Immunol 4: 335–379, 1984.Google Scholar
  7. 7.
    Steinman RM, Witmer MD: Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc Natl Acad Sci USA 75: 5132–5136, 1978.PubMedGoogle Scholar
  8. 8.
    Klinkert WEF, LaBadie JH, Bowers WE: Accessory and stimulating properties of dendritic cells and macrophages isolated from various rat tissues. J Erp Med 156: 1–19, 1982.Google Scholar
  9. 9.
    Unanue ER: Antigen-presenting function of the macrophage. Annu Rev Immunol 2: 395–428, 1984.PubMedGoogle Scholar
  10. 10.
    Singer A, Cowing C, Hathcock KS, Dickler HB, Hodes RJ: Cellular and genetic control of antibody responses in vitro. III. Immune response gene regulation of accessory cell function. J Erp Med 147: 1611–1620, 1978.Google Scholar
  11. 11.
    Swierkosz JE, Marrack P, Kappler JW: The role of H-2-linked genes in helper T cell function. V. I-region control of helper T-cell interaction with antigen-presenting macrophages. J Immunol 123: 654–659, 1979.PubMedGoogle Scholar
  12. 12.
    Watson J, Frank MB, Mochizuki D, Gillis S: The biochemistry and biology of interleukin-2. Lymphokines 6: 95–116, 1982.Google Scholar
  13. 13.
    Mitchison NA: Cell populations involved in immune responses. In Landy M, Braun W (eds): Immunological Tolerance, pp. 113–125. New York: Academic Press, 1969.Google Scholar
  14. 14.
    Taylor RB: Cellular cooperation in the antibody response of mice to two serum albumins: Specific function of thymus cells. Transplant Rev 1: 114–149, 1969.PubMedGoogle Scholar
  15. 15.
    Mitchison NA: The carrier effect in the secondary response to hapten-protein conjugates: II. Cellular cooperation. Eur J Immunol 1: 18–27, 1971.PubMedGoogle Scholar
  16. 16.
    Feldmann M, Basten A: The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med 134: 103–119, 1971.PubMedGoogle Scholar
  17. 17.
    Katz DH, Armerding D, Dorf ME, Eshhar Z, Benacerraf B: Control of immunocompetent cell differentiation and function by products of the major histocompatibility gene complex. In Eijsvoogel VP, Roos D, Zeijlemaker WP (eds): Leukocyte Membrane Determinants Regulating Immune Reactivity, pp. 269–284. New York: Academic Press, 1976.Google Scholar
  18. 18.
    Cantor H, Asofsky R: Synergy among lymphoid cells mediating the graft-versushost response. III. Evidence for interaction between two types of thymus-derived cells. J Exp Med 135: 764–779, 1972.PubMedGoogle Scholar
  19. 19.
    Wagner H: Synergy during in vitro cytotoxic allograft responses. I. Evidence for cell interaction between thymocytes and peripheral T cells. J Exp Med 138: 1379–1397, 1973.PubMedGoogle Scholar
  20. 20.
    Wagner H: Cell-mediated immune responses in vitro: Interaction of thymus-derived cells during cytotoxic allograft responses in vitro. Science 181: 1170–1172, 1973.PubMedGoogle Scholar
  21. 21.
    Huber B, Devinsky O, Gershon RK, Cantor H: Cell-mediated immunity: Delayed-type hypersensitivity and cytotoxic responses are mediated by different T-cell subclasses. J Exp Med 143: 1534–1539, 1976.PubMedGoogle Scholar
  22. 22.
    Crowle AJ: Delayed hypersensitivity in the mouse. Adv Immunol 20: 197–264, 1975.PubMedGoogle Scholar
  23. 23.
    Shreffler DC, David CS: The H-2 major histocompatibility complex and the I immune response region: Genetic variation, function and organization. Adv Immunol 20: 125–195, 1975.PubMedGoogle Scholar
  24. 24.
    Shearer GM, Schmitt-Verhulst A-M: Major histocompatibility complex restricted cell-mediated immunity. Adv Immunol 25: 55–91, 1977.PubMedGoogle Scholar
  25. 25.
    Zinkernagel RM, Doherty PC: MHC-restricted cytotoxic T cells: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol 27: 51–177, 1979.PubMedGoogle Scholar
  26. 26.
    Cantor H, Gershon RK: Immunological circuits: Cellular composition. Fed Proc 38: 2058–2064, 1979.PubMedGoogle Scholar
  27. 27.
    Yamauchi K, Fujimoto S, Tada T: Differential activation of cytotoxic and suppressor T cells against syngeneic tumors in the mouse. J Immunol 123: 1653–1658, 1979.PubMedGoogle Scholar
  28. 28.
    Perry LL, Dorf ME, Bach BA, Benacerraf B, Greene MI: Mechanisms of regulation of cell-mediated immunity: Anti-I-A alloantisera interfere with induction and expression of T-cell-mediated immunity to cell-bound antigen in vivo. Clin Immunol Immunopathol 15: 279–292, 1980.PubMedGoogle Scholar
  29. 29.
    Zembala MA, Asherson GL, James BMB, Stein VE, Watkins MC: Anti-hapten T suppressor factor acts through an I-J+, Lyt-1−2+, T acceptor cell that releases a nonspecific inhibitor of the transfer of contact sensitivity when exposed to antigen. J Immunol 129: 1823–1829, 1982.PubMedGoogle Scholar
  30. 30.
    Malkovsky M, Asherson GL, Chandler P, Colizzi V, Watkins MC, Zembala M: Nonspecific inhibitor of DNA synthesis elaborated by T acceptor cells. I. Specific hapten-and I-J-derived liberation of an inhibitor of cell proliferation by cyclophosphamide-sensitive T acceptor cells armed with a product of Lyt-1−2+-specific suppressor cells. J Immunol 130: 785–790, 1983.PubMedGoogle Scholar
  31. 31.
    Hellström KE, Hellström I: Cell-mediated suppression of tumor immunity has a nonspecific component. I. Evidence from transplantation tests. Int J Cancer 27: 481–485, 1981.PubMedGoogle Scholar
  32. 32.
    Sercarz EE, Yowell RL, Turkin D, Miller A, Araneo BA, Adorini L: Different functional specificity repertoires for suppressor and helper T cells. Immunol Rev 39: 108–136, 1978.PubMedGoogle Scholar
  33. 33.
    Jerne NK: Towards a network theory of the immune system. Ann Immunol 125C: 373–389, 1974.Google Scholar
  34. 34.
    Naor D: Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules. Cancer Immunol Immunother 16: 1–10, 1983.PubMedGoogle Scholar
  35. 35.
    Adorini L, Harvey MA, Miller A, Sercarz EE: Fine specificity of regulatory T-cells. II. Suppressor and helper T cells are induced by different regions of hen egg-white lysozyme in genetically nonresponder mouse strain. J Exp Med 150: 293–306, 1979.PubMedGoogle Scholar
  36. 36.
    Goodman JW, Sercarz EE: The complexity of structures involved in T-cell activation. Annu Rev Immunol 1: 465–498, 1983.PubMedGoogle Scholar
  37. 37.
    Swanborg RH: Antigen-induced inhibition of experimental allergic encephalomyelitis. III. Localization of an inhibitory site distinct from the major encephalitogenic determinant of myelin basic protein. J Immunol 114: 191–194, 1975.PubMedGoogle Scholar
  38. 38.
    Corradin G, Chiller JM: Lymphocyte specificity to protein antigens. III. Capacity of low responder mice to beef cytochrome C to respond to a peptide fragment of the molecule. Eur J Immunol 11: 115–119, 1981.PubMedGoogle Scholar
  39. 39.
    Allison AC: Mechanisms by which activated macrophages inhibit lymphocyte responses. Immunol Rev 40: 3–27, 1978.PubMedGoogle Scholar
  40. 40.
    Kung JT, Brooks SB, Jakway JP, Leonard LL, Talmage DW: Suppression of in vitro cytotoxic response by macrophages due to induced arginase. J Exp Med 146: 665–672, 1977.PubMedGoogle Scholar
  41. 41.
    Pierce CW, Aune TM: Mechanism of action of soluble immune response suppressor (SIRS): In Hadden J, Mullen P, Chedid L, Spreafico F (eds): Advances in Immunopharmacology, pp. 397–404. Oxford: Pergamon, 1981.Google Scholar
  42. 42.
    Morris NR, Fischer GA: Studies concerning the inhibition of cellular reproduction by deoxyribonucleosides. I. Inhibition of the synthesis of deoxycytidine by a phosphorylated derivative of thymidine. Biochem Biophys Acta 68: 84–92, 1963.Google Scholar
  43. 43.
    Optiz HG, Niethammer D, Lemke H, Flad H-D, Huget R: Inhibition of 3H-thymidine incorporation of lymphocytes by a soluble factor from macrophages. Cell Immunol 16: 379–388, 1975.Google Scholar
  44. 44.
    Optiz HG, Niethammer D, Jackson RC, Lemke H, Huget R, Flad H-D: Biochemical characterization of a factor released by macrophages. Cell Immunol 18: 70–75, 1975.Google Scholar
  45. 45.
    Uhr JW, Möller G: Regulatory effect of antibody on the immune response. Adv Immunol 8: 81–127, 1968.PubMedGoogle Scholar
  46. 46.
    Diener E, Feldmann M: Relationship between antigen and antibody-induced suppression of immunity. Transplant Rev 8: 76–103, 1972.PubMedGoogle Scholar
  47. 47.
    Rao VS, Bennett JA, Grodzicki RL, Mitchell MS: Suppressor T cells induced by soluble immune complexes can adoptively transfer inhibition of cytophilic antibody receptors on macrophages. Cell Immunol 46: 227–238, 1979.PubMedGoogle Scholar
  48. 48.
    Rajewsky K, Takemori T: Genetic expression and function of idiotypes. Annu Rev Immunol 1: 569–607, 1983.PubMedGoogle Scholar
  49. 49.
    Burnet FM: The concept of immunological surveillance. Prog Exp Tumor Res 13: 1–27, 1970.PubMedGoogle Scholar
  50. 50.
    Burnet FM: Immunological surveillance in neoplasia. Transplant Rev 7: 3–25, 1971.PubMedGoogle Scholar
  51. 51.
    Möller G, Möller E: Foreward: The concept of immunological surveillance against neoplasia. Transplant Rev 28: 3–16, 1976.PubMedGoogle Scholar
  52. 52.
    Prager MD, Baechtel FS: Methods for modification of cancer cells to enhance their antigenicity. Methods Cancer Res 9: 339–400, 1973.Google Scholar
  53. 53.
    Herberman RB: Cell-mediated immunity to tumor cells. Adv Cancer Res 19: 207–263, 1974.PubMedGoogle Scholar
  54. 54.
    Naor D, Galili N: Immune response to chemically modified antigens. Prog Allergy 22: 107–146, 1977.PubMedGoogle Scholar
  55. 55.
    Prehn RT, Main JM: Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18: 769–778, 1957.PubMedGoogle Scholar
  56. 56.
    Allison AC, Law LW: Effects of antilymphocyte serum on virus oncogenesis. Proc Soc Exp Biol Med 127: 207–212, 1968.PubMedGoogle Scholar
  57. 57.
    Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defense against cancer based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer 33: 241–259, 1976.PubMedGoogle Scholar
  58. 58.
    Rygaard J, Povlsen CO: The nude mouse vs. the hypothesis of immunological surveillance. Transplant Rev 28: 43–61, 1976.PubMedGoogle Scholar
  59. 59.
    Stutman O: Immunosuppression and malignancy. Adv Cancer Res 22: 261–422, 1975.PubMedGoogle Scholar
  60. 60.
    Klein G, Klein E: Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: Contrasting consequences of host versus tumor evolution. Proc Natl Acad Sci USA 74: 2121–2125.Google Scholar
  61. 61.
    Coggin JH, Anderson NG: Cancer, differentiation and embryonic antigens: Some central problems. Adv Cancer Res 19: 105–165, 1974.PubMedGoogle Scholar
  62. 62.
    Uriel J: Retrodifferentiation and the fetal patterns of gene expression in cancer. Adv Cancer Res 29: 127–174, 1979.PubMedGoogle Scholar
  63. 63.
    Schreiber H: Idiotype network interactions in tumor immunity. Adv Cancer Res 41: 291–321, 1984.PubMedGoogle Scholar
  64. 64.
    Kaliss N: Immunological enhancement of tumor homografts in mice: A review. Cancer Res 18: 992–1003, 1958.PubMedGoogle Scholar
  65. 65.
    Möller G: Effect on tumor growth in syngeneic recipients of antibodies against tumour-specific antigens in methylcholanthrene-induced mouse sarcomas. Nature 204: 846–847, 1964.PubMedGoogle Scholar
  66. 66.
    Voisin GA: Immunological facilitation, a broadening of the concept of the enhancement phenomenon. Prog Allergy 15: 328–485, 1971.PubMedGoogle Scholar
  67. 67.
    Brawn RJ: Evidence for association of embryonal antigen(s) with several 3-methylcholanthrene-induced murine sarcomas. In Anderson NG, Coggin JH (eds): Proceedings of the First Conference and Workshop on Embryonic and Fetal Antigens in Cancer, pp. 143–150. Oak Ridge, TN: Oak Ridge National Laboratory, 1971.Google Scholar
  68. 68.
    Alexander P: Fetal “antigens” in cancer. Nature 235: 137–140, 1972.PubMedGoogle Scholar
  69. 69.
    Baldwin RW, Price MR, Robins RA: Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumor-bearer serum, and solubilized hepatoma antigen. Int J Cancer 11: 527–535, 1973.PubMedGoogle Scholar
  70. 70.
    Vagge J: Specific desensitization of resistance against a syngeneic methylcholanthrene-induced sarcoma in C3Hf mice. Cancer Res 32: 193–199, 1972.Google Scholar
  71. 71.
    Sjögren HO, Hellström I, Bansal SC, Hellström KE: Suggestive evidence that the “blocking antibodies” of tumor-bearing individuals may be antigen-antibody complexes. Proc Natl Acad Sci USA 68: 1372–1375, 1971.PubMedGoogle Scholar
  72. 72.
    Baldwin RW, Price MR, Robins RA: Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumor-specific antigen-antibody complexes. Nature 238: 185–187, 1972.Google Scholar
  73. 73.
    Gershon RK, Mokyr MB, Mitchell MS: Activation of suppressor T cells by tumour cells and specific antibody. Nature 250: 594–596, 1974.PubMedGoogle Scholar
  74. 74.
    Nelson K, Pollack SB, Hellström KE: In vitro synthesis of tumor-specific factors with blocking and antibody-dependent cellular cytotoxicity (ADC) activities. Int J Cancer 16: 932–941, 1975.PubMedGoogle Scholar
  75. 75.
    Nepom JT, Hellström I, Hellström KE: Antigen-specific purification of blocking factors from sera of mice with chemically induced tumors. Proc Natl Acad Sci USA 74: 4605–4609, 1977.PubMedGoogle Scholar
  76. 76.
    Old LJ, Stocken E, Boyse EA, Kim JH: Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody, study of the phenomenon in vitro. J Exp Med 127: 523–539, 1968.PubMedGoogle Scholar
  77. 77.
    Urban JL, Burton RC, Holland JM, Kripke ML, Schreiber H: Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med 155: 557–573, 1982.PubMedGoogle Scholar
  78. 78.
    DeLustro F, Argyris BF: Mastocytoma-mediated suppression of mixed lymphocyte culture and mitogen responsiveness. Cell Immunol 21: 177–184, 1976.PubMedGoogle Scholar
  79. 79.
    DeLustro F, Argyris BF: Mechanism of mastocytoma-mediated suppression of lymphocyte reactivity. J Immunol 117: 2073–2080, 1976.PubMedGoogle Scholar
  80. 80.
    Kamo I, Friedman H: Immunosuppression and the role of suppressive factors in cancer. Adv Cancer Res 25: 271–321, 1977.PubMedGoogle Scholar
  81. 81.
    Werkmeister J, Zbroja R, McCarthy W, Hersey P: Detection of an inhibitor of cell division in cultures of tumor cells with immunosuppressive activity in vitro. Clin Exp Immunol 40: 168–177, 1980.PubMedGoogle Scholar
  82. 82.
    Roth JA: Tumor induced immunosuppression. Surg Gynecol Obstet 156: 233–240, 1983.PubMedGoogle Scholar
  83. 83.
    Plescia OJ, Smith AH, Grinwich K: Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 72: 1848–1851, 1975.PubMedGoogle Scholar
  84. 84.
    Fulton AM, Levy JG: Inhibition of murine tumor growth and prostaglandin synthesis by indomethacin. Int J Cancer 26: 669–673, 1980.PubMedGoogle Scholar
  85. 85.
    Pike MC, Snyderman R: Depression of macrophage function by a factor produced by neoplasms: A mechanism for abrogation of immune surveillance. J Immunol 117: 1243–1249, 1976.PubMedGoogle Scholar
  86. 86.
    Hellström KE, Hellström I: Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 18: 209–277, 1974.PubMedGoogle Scholar
  87. 87.
    Kirkwood JM, Gershon RK: A role for suppressor T cells in immunological enhancement of tumor growth. Prog Exp Tumor Res 19: 157–164, 1974.PubMedGoogle Scholar
  88. 88.
    Kirchner H, Glaser M, Holden HT, Fernbach BR, Herberman RB: Suppressor cells in tumor bearing mice and rats. Biomedicine 24: 371–374, 1976.PubMedGoogle Scholar
  89. 89.
    Broder S, Waldmann TA: The suppressor-cell network in cancer (First of two parts). N Engl J Med 299: 1281–1284, 1978.PubMedGoogle Scholar
  90. 90.
    Broder S, Waldmann TA: The suppressor-cell network in cancer (Second of two parts). N Engl J Med 299: 1335–1341, 1978.PubMedGoogle Scholar
  91. 91.
    Kirchner H: Perspectives in cancer research. Suppressor cells of immune reactivity in malignancy. Eur J Cancer 14: 453–459, 1978.PubMedGoogle Scholar
  92. 92.
    Mikulski SM, Muggia FM: The suppressor mechanisms and their significance in tumor immunology. Cancer Immunol Immunother 4: 139–142, 1978.Google Scholar
  93. 93.
    Oehler JR, Herberman RB, Holden HT: Modulation of immunity by macrophages. Pharmacol Ther [A] 2: 551–593, 1978.Google Scholar
  94. 94.
    Herberman RB, Holden HT, Djeu JY, Jerrells TR, Varesio L, Tagliabue A, White SL, Oehler JR, Dean JH: Macrophages as regulators of immune responses against tumors. In Escobar MR, Friedman H (eds): Macrophages and Lymphocytes: Nature, Functions and Interaction, Part B. Adv Exp Med Biol 121B:361–379. New York: Plenum Press, 1980.Google Scholar
  95. 95.
    Nepom GT, Hellström I, Hellström KE: Suppressor mechanisms in tumor immunity. Experientia 39: 235–242, 1983.PubMedGoogle Scholar
  96. 96.
    Feldmann M: Antigen specific T cell factors and their role in the regulation of T-B interaction. In Sercarz EE, Williamson AR, Fox CF (eds): The Immune System: Genes, Receptors, Signals, pp. 497–507. New York: Academic Press, 1974.Google Scholar
  97. 97.
    Gery I, Waksman BH: Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med 136: 143–155, 1972.PubMedGoogle Scholar
  98. 98.
    Stenson WF, Parker CW: Opinion. Prostaglandins, macrophages, and immunity. J Immunol 125: 1–5, 1980.PubMedGoogle Scholar
  99. 99.
    Connolly KM, Elgert KD: Concentration-dependent role of macrophages in mixed lymphocyte reaction regulation: Elaboration of nondialyzable heat-stable inhibitor and heat-labile enhancing factors. J Reticuloendothel Soc 25: 243–253, 1979.PubMedGoogle Scholar
  100. 100.
    Evans R, Alexander P: Mechanisms of extracellular killing of nucleated mammalian cells by macrophages. In Nelson DS (ed): Immunobiology of Macrophages, pp. 535–576. New York: Academic Press, 1976.Google Scholar
  101. 101.
    Haskill JS: ADCC effector cells in a murine adenocarcinoma. I. Evidence for blood-borne bone-marrow-derived monocytes. Int J Cancer 20: 432–440, 1977.PubMedGoogle Scholar
  102. 102.
    Key M, Haskill S: Macrophage-mediated, antibody-dependent destruction of tumor cells in DBA/2 mice: In vitro identification of an in situ mechanism. J Natl Cancer Inst 66: 103–110, 1981.PubMedGoogle Scholar
  103. 103.
    Kirchner H, Holden HT, Herberman RB: Inhibition of in vitro growth of lymphoma cells by macrophages from tumor-bearing mice. J Natl Cancer Inst 55: 971–975, 1975.PubMedGoogle Scholar
  104. 104.
    Männel DN, Falk W, Meltzer MS: Inhibition of nonspecific tumoricidal activity by activated macrophages with antiserum against a soluble cytotoxic factor. Infect Immun 33: 156–164, 1981.PubMedGoogle Scholar
  105. 105.
    Ruff MR, Gifford GE: Tumor necrosis factor. Lymphokines 2: 235–272, 1981.Google Scholar
  106. 106.
    Webb PJ, Brooks CG, Baldwin RW: Macrophage-like suppressor cells in rats. II. Evidence for quantitative rather than qualitative change in tumor-bearer animals. Cell Immunol 52: 381–394, 1980.PubMedGoogle Scholar
  107. 107.
    Elgert KD, Connolly KM: Macrophage regulation of the T-cell allogeneic response during tumor growth. Cell Immunol 35: 1–14, 1978.PubMedGoogle Scholar
  108. 108.
    Glaser M: Indomethacin-sensitive suppressor cells regulate the cell-mediated cytotoxic response to SV40-induced tumor-associated antigens in mice. Eur J Immunol 10: 489–495, 1980.PubMedGoogle Scholar
  109. 109.
    Mokyr MB, Hengst JCD, Przepiorka D, Dray S: Augmentation of antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of dinitrophenol-adherent cells prior to in vitro immunization. Cancer Res 39: 3928–3934, 1979.PubMedGoogle Scholar
  110. 110.
    Padarathsingh ML, Dean JH, Jerrels TR, McCoy JL, Lewis DD, Northing JW: Evidence for and characterization of suppressor cells in BALB/c mice bearing ADJ-PC5 plasmacytomas. J Natl Cancer Inst 62: 1235–1241, 1979.Google Scholar
  111. 111.
    Laing CA: Kinetics of the reactivity of subpopulations of spleen cells of mice bearing virus-induced mammary tumors to syngeneic antigenic extracts in vitro. Supportive and suppressive effects of macrophages. Cancer Immunol Immunother 13: 98–104, 1982.PubMedGoogle Scholar
  112. 112.
    Ye O W, Mokyr MB, Pyle JM, Dray S: Suppression of antitumor immunity by macrophages in spleens of mice bearing large MOPC-315 tumor. Cancer Immunol Immunother 16: 162–169, 1984.PubMedGoogle Scholar
  113. 113.
    Mokyr MB, Braun DP, Dray S: Augmentation of antitumor cytotoxicity in MOPC-315 tumor bearer spleen cells by depletion of glass-adherent cells prior to in vitro activition. Cancer Res 39: 785–792, 1979.PubMedGoogle Scholar
  114. 114.
    Hamburger AW: Inhibition of B-lymphocyte clonal proliferation by spleen cells from plasmacytoma-bearing mice. J Natl Cancer Inst 65: 1337–1343, 1980.PubMedGoogle Scholar
  115. 115.
    Gillespie GY, Hansen CB, Hoskins RG, Russell SW: Inflammatory cells in solid murine neoplasms. IV. Cytotoxic T lymphocytes isolated from regressing or progressing Moloney sarcomas. J Immunol 119: 564–570, 1977.PubMedGoogle Scholar
  116. 116.
    Gillespie GY, Russell SW: Development and persistence of cytolytic T lymphocytes in regressing of progressing Moloney sarcomas. Int J Cancer 21: 94–99, 1978.PubMedGoogle Scholar
  117. 117.
    Mokyr MB, Przepiorka D, Dray S: Augmenting anti-tumor cytotoxicity of tumor-bearer spleen cells. Proc Am Assoc Cancer Res 20: 13, 1979.Google Scholar
  118. 118.
    Forni G, Giovarelli M, Lanfrancone L, Varesio L: Suppressor macrophages in tumor-bearing mice. Inconsistency between in vivo and in vitro findings? Int J Cancer 29: 695–698, 1982.PubMedGoogle Scholar
  119. 119.
    Kirchner H, Chused TM, Herberman RB, Holden HT, Lavrin DH: Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med 139: 1473–1487, 1974.PubMedGoogle Scholar
  120. 120.
    Haskill JS, Proctor JW, Yamamura Y: Host responses within solid tumors. I. Monocyte effector cells within rat sarcomas. J Natl Cancer Inst 54: 387–393, 1975.PubMedGoogle Scholar
  121. 121.
    Holden HT, Haskill JS, Kirchner H, Herberman RB: Two functionally distinct antitumor effector cells isolated from primary murine sarcoma virus induced tumors. J Immunol 117: 440–446, 1976.PubMedGoogle Scholar
  122. 122.
    Russell SW, Doe WF, Hoskins RG, Cochrane DG: Inflammatory cells in solid murine neoplasms. I. Tumor disaggregation and identification of constituent inflammatory cells. Int J Cancer 18: 322–330, 1976.PubMedGoogle Scholar
  123. 123.
    Bluestone JA, Lopez C: Suppression of the immune response in tumor-bearing mice. II. Characterization of adherent suppressor cells. J Natl Cancer Inst 63: 1221–1227, 1979.PubMedGoogle Scholar
  124. 124.
    Varesio L, Jarrell EM, Landolfo S, Holden HT: Suppression of migration inhibition factor (MIF) production by macrophages from mice bearing MSV-induced tumors. Fed Proc 37: 1354, 1978 (Abstract 463).Google Scholar
  125. 125.
    Varesio L, Taramelli D, Holden HT: Suppression of early events of lymphocyte activation by macrophages from mice bearing MSV-induced tumors. Fed Proc 38: 1470, 1979.Google Scholar
  126. 126.
    Varesio L, Herberman RB, Gerson JM, Holden HT: Suppression of lymphokine production by macrophages infiltrating murine virus-induced tumors. Int J Cancer 24: 97–102, 1979.PubMedGoogle Scholar
  127. 127.
    Varesio L, Holden HT: Suppression of lymphokine production. I. Macrophages-mediated inhibition of MIF production. Cell Immunol 56: 16–28, 1980.PubMedGoogle Scholar
  128. 128.
    Holden HT, Varesio L, Taniyama T, Puccetti P: Functional heterogeneity and T cell-dependent activation of macrophages from murine sarcoma virus (MSV)-induced tumors. In Escobar MR, Friedman H (eds): Macrophages and Lymphocytes: Nature, Functions and Interaction, Part B. Adv Fxp Med Biol 121B: pp 509–520. New York: Plenum Press, 1980.Google Scholar
  129. 129.
    Varesio L, Holden HT: Regulation of lymphocyte activation: Macrophage-dependent suppression of T lymphocyte protein synthesis. J Immunol 125: 1694–1701, 1980.PubMedGoogle Scholar
  130. 130.
    Farrar WL, Elgert KD: Inhibition of mitogen and immune blastogenesis by two distinct populations of suppressor cells present in the spleens of fibrosarcoma-bearing mice: Adoptive transfer of suppression. Int J Cancer 22: 142–151, 1978.PubMedGoogle Scholar
  131. 131.
    Elgert KD, Farrar WL: In vitro immune blastogenesis during contact sensitivity in tumor-bearing mice. I. Description of progressive impairment and demonstration of splenic suppressor cells. Cell Immunol 40: 356–364, 1978.PubMedGoogle Scholar
  132. 132.
    Farrar WL, Elgert KD: In vitro immune blastogenesis during contact sensitivity in tumor-bearing mice. II. Mechanism of inhibition. Cell Immunol 40: 365–375, 1978.PubMedGoogle Scholar
  133. 133.
    Connolly KM, Farrar WL, Elgert KD: Tumor-induced dualistic suppressor cell regulation: Macrophages and suppressor T cells. In Quastel MR (ed): Cell Biology and Immunology of Leukocyte Function, pp. 701–705. New York: Academic Press, 1979.Google Scholar
  134. 134.
    Connolly KM, Elgert KD: Regulation of T-cell mixed lymphocyte reaction reactivity: Demonstration of enhancing and inhibitory activity in tumor-bearing host macrophage supernatants. Cell Immunol 45: 94–107, 1979.PubMedGoogle Scholar
  135. 135.
    Connolly KM, Elgert KD: Reversal of macrophage-augmented MLR reactivity by tumor-induced splenic suppressor T cells and their soluble factor(s). Cell Immunol 44: 99–108, 1979.PubMedGoogle Scholar
  136. 136.
    Elgert KD, Connolly KM: Enhancement of T cell MLR reactivity by addition of macrophage supernatants from tumor-bearing mice. Oncology 37: 101–106, 1980.PubMedGoogle Scholar
  137. 137.
    Connolly KM, Elgert KD: Positive and negative blastogenic regulation by tumor-bearing mouse T cells. J Reticuloendothel Soc 28: 27–35, 1980.PubMedGoogle Scholar
  138. 138.
    Farrar WL, Elgert KD, See-Yan Foo A: Suppressor cell activity in tumor-bearing mice. III. Co-purification of a factor inhibiting cellular DNA synthesis and DNA polymerase activity. J Immunol 127: 2339–2344, 1981.PubMedGoogle Scholar
  139. 139.
    Denbow CJ, Black SP, Conroy JM, Elgert KD: Macrophage-derived factor regulation in normal and tumor-bearing hosts. Fed Proc 41: 845, 1982.Google Scholar
  140. 140.
    Denbow CJ, Conroy JM, Elgert KD: Macrophage-derived prostaglandin E modulation of the mixed lymphocyte reaction: An anomaly of increased production and decreased T-cell susceptibility during tumor growth. Cell Immunol 84: 1–13, 1984.PubMedGoogle Scholar
  141. 141.
    Malick AP, Garner RE, Black SP, Elgert KD: Normal and tumor-bearing host macrophage factor-mediated modulation of mixed-lymphocyte reaction responsiveness: Separation of T-lymphocyte subset susceptibility to enhancing and inhibitory factors. Cell Immunol 85: 549–555, 1984.PubMedGoogle Scholar
  142. 142.
    Shibata Y, Shibuya E, Ishida N: Relationships between suppressor macrophages and macrophages precursors in the spleens from tumor-bearing mice. Cell Immunol 85: 45–57, 1984.PubMedGoogle Scholar
  143. 143.
    Weiss A, Fitch FW: Macrophages suppressor CTL generation in rat mixed leukocyte cultures. J Immunol 119: 510–516, 1977.PubMedGoogle Scholar
  144. 144.
    Varesio L, Giovarelli M, Landolfo S, Forni G: Suppression of proliferative response and lymphokine production during the progression of a spontaneous tumor. Cancer Res 39: 4983–4988, 1979.PubMedGoogle Scholar
  145. 145.
    Varesio L, Holden HT, Taramelli D: Suppression of lymphokine production. II. Macrophage-dependent inhibition of production of macrophage activating factor. Cell Immunol 63: 279–292, 1981.PubMedGoogle Scholar
  146. 146.
    Gillespie GY, Russell SW: Level of activation determines whether inflammatory peritoneal and intratumoral macrophages will promote or suppress in vitro development of cytolytic T lymphocyte activity. J Reticuloendothel Soc 27: 535–545, 1980.PubMedGoogle Scholar
  147. 147.
    Plata F, MacDonald HR, Shain B: Suppressor T cells regulate the cytolytic T lymphocyte response to syngeneic tumors induced by murine sarcoma virus (MSV) in the mouse. J Immunol 123: 852–860, 1979.PubMedGoogle Scholar
  148. 148.
    Pelus LM, Bockman RS: Increased prostaglandin synthesis by macrophages from tumor-bearing mice. J Immunol 123: 2118–2125, 1979.PubMedGoogle Scholar
  149. 149.
    Pelus LM, Strausser HR: Indomethacin enhancement of spleen-cell responsiveness to mitogen stimulation in tumorous mice. Int J Cancer 18: 653–660, 1976.PubMedGoogle Scholar
  150. 150.
    Garrigues HJ, Romero P, Hellström I, Hellström KE: Adherent cells (macrophages) in tumor-bearing mice suppress MLC responses. Cell Immunol 60: 109–118, 1981.PubMedGoogle Scholar
  151. 151.
    Ting C-C, Hargrove ME: Tumor cell-triggered macrophage-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. II. Mechanisms for induction of suppression. J Natl Cancer Inst 69: 873–878, 1982.PubMedGoogle Scholar
  152. 152.
    Shibata Y, Tamura K, Ishida N: In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of a,-acid glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Res 43: 2889–2896, 1983.PubMedGoogle Scholar
  153. 153.
    Kedar E, Katz-Gross A, Chriqui-Zeira E, Bercowitz H: Suppression by tumor growth of T-cell growth factor production in mouse lymphoid cell cultures. J Biol Resp Modif 3: 547–560, 1984.Google Scholar
  154. 154.
    Kataoka T, Oh-hashi F, Sakurai Y: Suppressor macrophages in tumor-bearing mice and their selective inhibition by 6-mercaptopurine. Cancer Res 45: 2139–2144, 1985.PubMedGoogle Scholar
  155. 155.
    Young MR, Simmermaker JA: Prostaglandin E2 regulation of tumoristatic factor production by macrophage-like P388D1 cells. JNatl Cancer lnst 73: 959–962, 1984.Google Scholar
  156. 156.
    Alberghina L, Mariani L: Control of cell growth and division. In Valleron M, MacDonald PDM (eds): Biomathematics and Cell Kinetics, pp. 89–120. Amsterdam: Elsevier/North Holland, 1978.Google Scholar
  157. 157.
    Milner J: Is protein synthesis necessary for the commitment of lymphocyte transformation? Nature 272: 628–629, 1978.PubMedGoogle Scholar
  158. 158.
    Henney CS, Gaffney J, Bloom BR: On the relation of products of activated lymphocytes to cell-mediated cytolysis. J Exp Med 140: 837–852, 1974.PubMedGoogle Scholar
  159. 159.
    Unanue ER, Kiely J-M: Synthesis and secretion of a mitogenic protein by macrophages: Description of a superinduction phenomenon. J Immunol 119: 925–931, 1977.PubMedGoogle Scholar
  160. 160.
    Vileek J, Ng MH: Post-transcriptional control of interferon synthesis. J Virol 7: 588–594, 1971.Google Scholar
  161. 161.
    Moody CE Jr, Tunticharoen M, Laux DC: Increased cell-mediated lysis of chicken erythrocytes following the addition of metabolic inhibitors. Immunology 33: 285–293, 1977.PubMedGoogle Scholar
  162. 162.
    Nedrud J, Touton M, Clark WR: The requirement for DNA synthesis and gene expression in the generation of cytotoxicity in vitro. J Exp Med 142: 960–973, 1975.PubMedGoogle Scholar
  163. 163.
    Stall AM, Knopf PM: The effect of inhibitors of protein synthesis on the reexpression of surface immunoglobulin following antigenic modulation. Cell 14: 33–42, 1978.PubMedGoogle Scholar
  164. 164.
    Kennard J, Zolla-Pazner S: Origin and function of suppressor macrophages in myeloma. J Immunol 124: 268–273, 1980.PubMedGoogle Scholar
  165. 165.
    Chen Y, Heller P: The mode of action of splenic suppressor cells in murine plasmacytoma. Clin Exp Immunol 45: 514–522, 1981.PubMedGoogle Scholar
  166. 166.
    Chen Y, Hwang LT, Heller P: Immunosuppression in plasmacytoma: Induction of suppressor cells. Clin Exp Immunol 47: 191–196, 1982.PubMedGoogle Scholar
  167. 167.
    Chen Y-H, Heller P: Suppressor activity of splenic macrophages in murine plasmacytoma (PC) is inhibited by PC specific ligands. Clin Exp Immunol 50: 366–373, 1982.PubMedGoogle Scholar
  168. 168.
    Ullrich S, Zolla-Pazner S: Immunoregulatory circuits in myeloma. Clin Haematol 11: 87–111, 1982.PubMedGoogle Scholar
  169. 169.
    Katzmann JA: Myeloma-induced immunosuppression: A multistep mechanism. J Immunol 121: 1405–1409, 1978.PubMedGoogle Scholar
  170. 170.
    Krakauer RS, Strober W, Waldmann TA: Hypogammaglobulinemia in experimental myeloma: The role of suppressor factors from mononuclear phagocytes. J Immunol 118: 1385–1390, 1977.PubMedGoogle Scholar
  171. 171.
    Krakauer RS, Strober W, Waldmann TA: Hypogammaglobulinemia in experimental myeloma: The role of suppressor mononuclear phagocyes. Clin Res 24: 377A, 1976.Google Scholar
  172. 172.
    Wang KC, Berczi I, Sehon AH: Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay. Int J Cancer 25: 487–492, 1980.PubMedGoogle Scholar
  173. 173.
    Argyris BF, Horowitz M: Cell interaction in tumor allograft immunity. Suppressor cell in the spleen of allogeneic tumor-sensitized mice. Transplantation 22: 112–121, 1976.PubMedGoogle Scholar
  174. 174.
    Ting C-C, Rodrigues D, Ting RC, Wivel N, Collins MJ: Suppression of T-cellmediated immunity by tumor cells: Immunogenicity versus immunosuppression and preliminary characterization of the suppressive factors. Int J Cancer 24: 644–655, 1979.PubMedGoogle Scholar
  175. 175.
    Ting C-C, Rodrigues D: Reversal by peritoneal adherent cells of tumor cell suppression of the T-cell mediated immunity. J Immunol 123: 801–807, 1979.PubMedGoogle Scholar
  176. 176.
    Ting C-C, Rodrigues D: Immunoregulatory circuit among macrophage subsets for T cell-mediated cytotoxic response to tumor cells. J Immunol 124: 1039–1044, 1980.PubMedGoogle Scholar
  177. 177.
    Ting C-C, Rodrigues D: Switching on the macrophage-mediated suppressor mechanism by tumor cells to evade host immune surveillance. Proc Natl Acad Sci USA 77: 4265–4269, 1980.PubMedGoogle Scholar
  178. 178.
    Ting C-C, Rodrigues D: Increased susceptibility to tumor cell immunosuppressive effect in tumor-bearing mice. J Natl Cancer Inst 65: 205–209, 1980.PubMedGoogle Scholar
  179. 179.
    Ting C-C, Rodrigues D: Evaluation of the immunocompetence of macrophages and the generation of T-cell-mediated cytotoxic response against allogenic tumor cells in tumor bearers. Int J Cancer 25: 243–249, 1980.PubMedGoogle Scholar
  180. 180.
    Ting C-C, Rodrigues D: Tumor cell-triggered macrophages-mediated suppression of the T-cell cytotoxic response to tumor-associated antigens. I. Characterization of the cell components for induction of suppression. J Natl Cancer Inst 69: 867–872, 1982.PubMedGoogle Scholar
  181. 181.
    Roder JC, Tyler L, Ball JK, Singhal SK: The immunocompetence of tumor T cells and their role in generalized immunosuppression and immunostimulation following inoculation of dimethylbenzanthracene-induced leukemia virus in mice. Cell Immunol 36: 128–142, 1978.PubMedGoogle Scholar
  182. 182.
    Jessup JM, Macek CM, Kahan BD, Pellis NR: Effect of murine tumors upon delayed hypersensitivity to dinitrochlorobenzene. III. In vivo activity of the nonspecific suppressor cell. J Immunol 127:2183–2187, 1981.Google Scholar
  183. 183.
    Wood GW, Gillespie Y: Studies on the role of macrophages in regulation of growth and metastasis of murine chemically induced fibrosarcoma. Int J Cancer 16: 1022–1029, 1975.PubMedGoogle Scholar
  184. 184.
    Saito M, Nanjo M, Aonuma E, Noda T, Nakadate I, Ebina T, Ishida N: Activated macrophages are responsible for the tumor-inhibitory effect in mice receiving intravenous injection of OK-432. Int J Cancer 33: 271–276, 1984.PubMedGoogle Scholar
  185. 185.
    Strausser HR, Humes JL: Prostaglandin synthesis inhibition: Effect on, bone changes and sarcoma tumor induction in BALB/c mice. Int J Cancer 15: 724–730, 1975.PubMedGoogle Scholar
  186. 186.
    Schultz RM, Pavlidis NA, Stylos WA, Chirigos MA: Regulation of macrophage tumoricidal function: A role for prostaglandins of the E series. Science 202: 320–321, 1978.Google Scholar
  187. 187.
    Schultz RM, Pavlidis NA, Stoychkov JN, Chirigos MA: Prevention of macrophage tumoricidal activity by agents known to increase cellular cyclic AMP. Cell Immunol 42: 71–78, 1979.PubMedGoogle Scholar
  188. 188.
    Taffet SM, Russell SW: Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J Immunol 126: 424–427, 1981.Google Scholar
  189. 189.
    Shaw JO, Russell SW, Printz MP, Skidgel RA: Macrophage-mediated tumor cell killing: Lack of dependence on the cyclooxygenase pathway of prostaglandin synthesis. J Immunol 123: 50–54, 1979.PubMedGoogle Scholar
  190. 190.
    Powles TJ, Clark SA, Easty DM, Easty GC, Neville AM: The inhibition by aspirin and indomethacin of osteolytic tumour deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. Br J Cancer 28: 316–321, 1973.PubMedGoogle Scholar
  191. 191.
    Plescia OJ, Smith AH, Grinwich K: Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl Acad Sci USA 72: 1848–1851, 1975.PubMedGoogle Scholar
  192. 192.
    Hial V, Horakova Z, Shaff RE, Beaven MA: Alternation of tumor growth by aspirin and indomethacin: Studies with two transplantable tumors in mouse. Eur J Pharmacol 37: 367–376, 1976.PubMedGoogle Scholar
  193. 193.
    Lynch NR, Gastes M, Astoin M, Salomon J-C: Mechanism of inhibition of tumour growth by aspirin and indomethacin. Br J Cancer 38: 503–512, 1978.PubMedGoogle Scholar
  194. 194.
    Bennet A, Houghton J, Leaper DJ, Stamford IF: Cancer growth, response to treatment and survival time in mice: Beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prostaglandins 17: 179–191, 1979.Google Scholar
  195. 195.
    Honn KV, Bockman RS, Marnett LJ: Prostaglandins and cancer: A review of tumor initiation through tumor metastasis. Prostaglandins 21: 833–864, 1981.PubMedGoogle Scholar
  196. 196.
    Fulton AM: In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res 44: 2416–2420, 1984.PubMedGoogle Scholar
  197. 197.
    Santoro MG, Philpott GW, Jaffe BM: Inhibition of tumour growth in vivo and in vitro by prostaglandin E. Nature 263: 777–779, 1976.Google Scholar
  198. 198.
    Jubiz W, Frailey J, Smith JB: Inhibitory effect of prostaglandin Fla on the growth of a hormone-dependent rat mammary tumor. Cancer Res 39: 998–1000, 1979.PubMedGoogle Scholar
  199. 199.
    Lubet RA, Carlson DE: Therapy of the murine plasmacytoma MOPC 104E: Role of the immune response. J Natl Cancer Inst 61: 897–903, 1978.PubMedGoogle Scholar
  200. 200.
    Hengst JCD, Mokyr MB, Dray S: Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice. Cancer Res 40: 2135–2141, 1980.PubMedGoogle Scholar
  201. 201.
    Hengst JCD, Mokyr MB, Dray S: Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Res 41: 2163–2167, 1981.PubMedGoogle Scholar
  202. 202.
    Mokyr MB, Dray S: Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide. Cancer Res 43: 3112–3119, 1983.PubMedGoogle Scholar
  203. 203.
    Ye Q-W, Mokyr MB: Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor. Cancer Res 44: 3873–3879, 1984.PubMedGoogle Scholar
  204. 204.
    Mokyr MB, Dray S: Cyclophosphamide-mediated selective elimination of suppressor cell activity from the spleen of mice bearing a large MOPC-315 tumor. Proc Am Assoc Cancer Res 24: 204, 1983.Google Scholar
  205. 205.
    Kataoka T, Oh-Hashi F, Tsukagoshi S, Sakurai Y: Induction of resistance to L1210 leukemia in (BALB/c x DBA/2Cr)F, mice, with L1210 cells treated with glutaraldehyde and concanavalin A. Cancer Res 37: 964–968, 1977.PubMedGoogle Scholar
  206. 206.
    Kataoka T, Kobayashi H, Sakurai Y: Potentiation of concanavalin A-bound L1210 vaccine in vivo by chemotherapeutic agents. Cancer Res 38: 1202–1207, 1978.PubMedGoogle Scholar
  207. 207.
    Kataoka T, Oh-Hashi F, Sakurai Y, Okabe M, Gomi K: Factors responsible for immune resistance to L1210 murine leukemia in hyperimmune mice. Cancer Immunol Immunother 7: 123–129, 1979.Google Scholar
  208. 208.
    Kataoka T, Oh-Hashi F, Sakurai Y, Gomi K: In vivo potentiation of concanavalin Abound L1210 vaccine by antimacrophage agents. Cancer Res 40: 3832–3838, 1980.PubMedGoogle Scholar
  209. 209.
    Kataoka T, Ogihara K, Sakurai Y: Immunoprophylactic and immunotherapeutic response by concanavalin-A bound tumor vaccine enhanced by chemotherapeutic agents eliminating possible suppressors. Cancer Res 40: 3839–3845, 1980.PubMedGoogle Scholar
  210. 210.
    Kataoka T, Oh-Hashi F, Sakurai Y, Ogihara K: Effect of antineoplastic agents on the induction of suppressor macrophages by concanavalin A-bound tumor vaccine. Cancer Res 41: 5151–5157, 1981.PubMedGoogle Scholar
  211. 211.
    Kataoka T, Akahori Y, Sakurai Y: 6-Mercaptopurine (6-MP)-induced potentiation of active immunotherapy in L1210-bearing mice by eliminating suppressor macrophages. Proc Am Assoc Cancer Res 24: 204, 1983.Google Scholar
  212. 212.
    Kataoka T, Akahori Y, Sakurai Y: 6-Mercaptopurine-induced potentiation of active immunotherapy in Ll 210-bearing mice treated with concanavalin A-bound leukemia cell vaccine. Cancer Res 44: 519–524, 1984.PubMedGoogle Scholar
  213. 213.
    Kedar E, Weiss DW: The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res 38: 171–287, 1983.PubMedGoogle Scholar
  214. 214.
    Winn HJ: The immune response and the homograft reaction. Natl Cancer Inst Monogr 2: 113–138, 1960.PubMedGoogle Scholar
  215. 215.
    Ting C-C, Zhang S-R: Studies of the mechanisms for the induction of in vivo tumor immunity. VII. Development of specific antitumor immunity in progressors and regressors. Int J Cancer 32: 385–391, 1983.PubMedGoogle Scholar
  216. 216.
    Feldman JD, Fernandez-Cruz E: Immunotherapy of tumors in vivo with effector cells generated in vitro. In Weigle WO (ed): Advances in Immunopathology, pp. 315–336. Amsterdam: Elsevier/North Holland, 1981.Google Scholar
  217. 217.
    Fernandez-Cruz E, Feldman JD: Immunotherapy of progressive tumors with T cell subsets. In Fefer A, Goldstein AL (eds): The Potential Role of T-cells in Cancer Therapy, pp. 53–63. New York: Raven Press, 1982.Google Scholar
  218. 218.
    Fernandez-Cruz E, Gilman SC, Feldman JD: Immunotherapy of a chemically-induced sarcoma in rats: Characterization of the effector T cell subset and nature of suppression. J Immunol 128: 1112–1117, 1982.PubMedGoogle Scholar
  219. 219.
    White RAH, Manson DW, Williams AF, Galfre G, Milstein C: T-lymphocyte heterogeneity in the rat: Separation of functional subpopulations using a monoclonal antibody. J Exp Med 148: 664–673, 1978.PubMedGoogle Scholar
  220. 220.
    Lee LF, Sharma JM, Nazerian K, Witter RL: Suppression of mitogen-induced proliferation of normal spleen cells by macrophages from chickens inoculated with Marek’s disease virus. J Immunol 120: 1554–1559, 1978.PubMedGoogle Scholar
  221. 221.
    Hakim AA: Correlation between immunosuppression to tumorigenesis. I. Humoral immunosuppressive factor. Eur J Cancer 14: 1249–1260, 1978.PubMedGoogle Scholar
  222. 222.
    Anaclerio A, Moras ML, Conti G, Mistrello G, Spreafico F: Suppression of mitogen responses and graft-versus-host reaction by splenocytes from mice bearing Lewis lung carcinoma. J Natl Cancer Inst 61: 471–475, 1978.PubMedGoogle Scholar
  223. 223.
    Katzmann J, Bhoopalam N, Heller P, Hwang L-T, Ostro M, Lavelle D, Giacomoni D: Role of intracisternal A particles and of RNA molecules in plasmacytoma-associated immunodeficiency. Cancer Res 38: 2555–2561, 1978.PubMedGoogle Scholar
  224. 224.
    Jessup JM, Pellis NR, Kahan BD: The spleen as a source of nonspecific suppressor cells in the tumor-bearing mouse. J Surg Res 28: 460–465, 1980.PubMedGoogle Scholar
  225. 225.
    Gerson JM, Varesio L, Herberman RB: Systemic and in situ natural killer and suppressor cell activities in mice bearing progressively growing murine sarcoma-virusinduced tumors. Int J Cancer 27: 243–248, 1981.PubMedGoogle Scholar
  226. 226.
    Manor Y, Treves AJ, Cohen IR, Feldman M: Transition from T cell protection to T cell enhancement during tumor growth in an allogeneic host. Transplantation 22: 360–366, 1976.PubMedGoogle Scholar
  227. 227.
    Kimura H, Aoki T: Enhancing and inhibiting effects of spleen cells from tumour-bearing mice on growth of virus-induced primary sarcoma. Br J Cancer 37: 553–565, 1978.PubMedGoogle Scholar
  228. 228.
    Hellström I, Hellström KE, Bernstein ID: Tumor-enhancing suppressor activator T cells in spleens and thymuses of tumor immune mice. Proc Natl Acad Sci USA 76: 5294–5298, 1979.PubMedGoogle Scholar
  229. 229.
    Mule JJ, Forstrom JW, George E, Hellström I, Hellström KE: Production of T-cell lines with inhibitory or stimulatory activity against syngeneic tumors in vivo. A preliminary report. Int J Cancer 28: 611–614, 1981.PubMedGoogle Scholar
  230. 230.
    Ilfeld D, Carnaud C, Cohen IR, Trainin N: In vitro cytotoxicity and in vivo tumor enhancement induced by mouse spleen cells autosensitized in vitro. Int J Cancer 12: 213–222, 1973.PubMedGoogle Scholar
  231. 231.
    Small M, Trainin N: Separation of populations of sensitized lymphoid cells into fractions inhibiting and fractions enhancing syngeneic tumor growth in vivo. J Immunol 117: 292–297, 1976.PubMedGoogle Scholar
  232. 232.
    Prehn RT, Lappé MA: An immunostimulation theory of tumor development. Transplant Rev 7: 26–54, 1971.PubMedGoogle Scholar
  233. 233.
    Greene MI, Fujimoto S, Sehon AH: The characterization of thymic suppressor factor(s) regulating the immune response to tumor antigens. In Peeters, H (ed): Protides of the Biological Fluids, pp. 677–684. New York: Pergamon Press, 1978.Google Scholar
  234. 234.
    Greene MI, Perry LL: Regulation of the immune response to tumor antigen. VI. Differential specificities of suppressor T cells or their products and effector T cells. J Immunol 121: 2363–2366, 1978.PubMedGoogle Scholar
  235. 235.
    Perry LL, Benacerraf B, Greene MI: Regulation of the immune response to tumor antigen. IV. Tumor antigen-specific suppressor factor(s) bear I-J determinants and induce suppressor T cells in vivo. J Immunol 121: 2144–2147, 1978.PubMedGoogle Scholar
  236. 236.
    Greene MI, Perry LL, Benacerraf B: The genetic basis of the cellular and molecular regulation of the immune response to tumor antigen. In Kilburn DG, Levy JG, Teh H-S (eds): Regulation by T Cells, p. 114. Vancouver: University of British Columbia, 1979.Google Scholar
  237. 237.
    Perry LL, Dorf ME, Benacerraf B, Greene MI: Regulation of immune response to tumor antigen: Interference with syngeneic tumor immunity by anti-I-A alloantisera. Proc Natl Acad Sci USA 76: 920–924, 1979.PubMedGoogle Scholar
  238. 238.
    Greene MI: The genetic and cellular basis of regulation of the immune response to tumor antigens. Cont Topics Immunobiol 11: 81–116, 1980.Google Scholar
  239. 239.
    Greene MI, Perry LL: The relationship of alloreactivity to syngeneic tumor immunity. Transplant Proc 12: 80–86, 1980.PubMedGoogle Scholar
  240. 240.
    Perry LL, Dorf ME, Bach BA, Benacerraf B, Greene MI: Mechanisms of regulation of cell-mediated immunity: Anti-I-A alloantisera interfere with induction and expression of T-cell-mediated immunity to cell-bound antigen in vivo. Clin Immunol Immunopathol 15: 279–292, 1980.PubMedGoogle Scholar
  241. 241.
    Perry LL, Greene MI: T cells subset interactions in the regulation of syngeneic tumor immunity. Fed Proc 40: 39–44, 1981.PubMedGoogle Scholar
  242. 242.
    Bhan AK, Perry LL, Cantor H, McCluskey RT, Benacerraf B, Greene MI: The role of T cells sets in the rejection of a methylcholanthrene-induced sarcoma (S 1509a) in syngeneic mice. Am J Pathol 102: 20–27, 1981.PubMedGoogle Scholar
  243. 243.
    Schatten S, Drebin JA, Takaoki M, Carter R, Tominaga A, Abbas AK, Finberg R, Greene MI: Regulation of the immune response to cell surface antigens. In Vitetta ES (ed): UCLA Symposia on Molecular and Cellular Biology, pp. 349–368. New York: Academic Press, 1982.Google Scholar
  244. 244.
    Perry LL, Greene MI: Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies. J Exp Med 156: 480–491, 1982.PubMedGoogle Scholar
  245. 245.
    Carter RH, Drebin JA, Schatten S, Perry LL, Greene MI: Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2 cell proliferative responses to cellbound or subcellular tumor antigen. J Immunol 130:997–1002, 1983.PubMedGoogle Scholar
  246. 246.
    Schatten S, Drebin JA, Perry LL, Chung W, Greene MI: Regulation of the immune response to tumor antigens. X. Activation of third-order-suppressor T cells that abrogate anti-tumor immune responses. J Immunol 133: 1064–1069, 1984.PubMedGoogle Scholar
  247. 247.
    Fujimoto S, Tada T: I region expression on cytotoxic and suppressor T cells against syngeneic tumors in the mouse. GANN Monogr Cancer Res 21: 11–20, 1978.Google Scholar
  248. 248.
    Fujimoto S, Matsuzawa T, Nakagawa K, Tada T: Cellular interaction between cytotoxic and suppressor T cells against syngeneic tumors in the mouse. Cell Immunol 38: 378–387, 1978.PubMedGoogle Scholar
  249. 249.
    Yamauchi K, Fujimoto S, Tada T: Differential activation of cytotoxic and suppressor T cells against syngeneic tumors in the mouse. J Immunol 123: 1653–1658, 1979.PubMedGoogle Scholar
  250. 250.
    Embleton MJ: Influence of cell-free tumour-associated antigen preparations on the development of immunity to chemically induced rat tumours. Int J Cancer 18: 622–629, 1976.PubMedGoogle Scholar
  251. 251.
    LeGrue SJ, Hearn DR: Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low and high metastatic potentials. Cancer Res 43: 5106–5111, 1983.PubMedGoogle Scholar
  252. 252.
    Sy MS, Dietz MH, Germain RN, Benacerraf B, Greene MI: Antigen-and receptor-driven regulatory mechanisms. IV. Idiotype-bearing I-J+ suppressor T cell factors induce second-order suppressor T cells which express anti-idiotypic receptors. J Exp Med 151: 1183–1195, 1980.PubMedGoogle Scholar
  253. 253.
    Dietz MH, Sy M-S, Benacerraf B, Nisonoff A, Greene MI, Germain RN: Antigen-and receptor-driven regulatory mechanisms. VII. H-2-restricted anti-idiotypic suppressor factor from efferent suppressor T cells. J Exp Med 153: 450–463, 1981.PubMedGoogle Scholar
  254. 254.
    Hawrylko E: Augmentation of BCG-potentiated delayed type hypersensitivity (DTH) and antitumor immunity by cyclophosphamide. Am Assoc Cancer Res 20: 273, 1979.Google Scholar
  255. 255.
    Hawrylko E: Induction of delayed-type hypersensitivity and anti-tumor immunity by systemic BCG. Cell Immunol 50: 136–152, 1980.PubMedGoogle Scholar
  256. 256.
    Hawrylko E: Tumor-bearer T cells suppress BCG-potentiated anti-tumor responses. I. Requirements for their effect. Cell Immunol 66: 121–138, 1982.PubMedGoogle Scholar
  257. 257.
    Hawrylko E, Mele CA, Stutman O: Tumor-bearer T cells suppress BCG-potentiated anti-tumor responses. II. Characteristics of the efferent phase suppressor. Cell Immunol 66: 139–151, 1982.PubMedGoogle Scholar
  258. 258.
    Hawrylko E, Mele CA: Suppressor T cell circuit in tumor-bearing mice. Fed Proc 42: 1081, 1983.Google Scholar
  259. 259.
    Hawrylko E, Mele CA: Tumor bearer T cells suppress Bacillus Calmette-Guerin potentiated antitumor responses. III. Identification of an auxiliary efferent suppressor T cell popuulation. Cell Immunol 87: 566–579, 1984.PubMedGoogle Scholar
  260. 260.
    Hellström KE, Hellström I, Kant JA, Tamerius JD: Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J Exp Med 148: 799–804, 1978.PubMedGoogle Scholar
  261. 261.
    Nelson K, Cory J, Hellström I, Hellström KE: T-T hybridoma product specifically suppresses tumor immunity. Proc Natl Acad Sci USA 77: 2866–2870, 1980.PubMedGoogle Scholar
  262. 262.
    Mulé JJ, Stanton TH, Hellström I, Hellström KE: Suppressor pathways in tumor immunity: A requirement for Qa-1 positive tumor-bearer spleen T cells in suppression of the afferent immune response to tumor antigens. Int J Cancer 28: 353–359, 1981.PubMedGoogle Scholar
  263. 263.
    Mitchell MS, Mokyr MB: Specific inhibition of receptors for cytophilic antibody on macrophages by isoantibody. Cancer Res 32: 832–838, 1972.PubMedGoogle Scholar
  264. 264.
    Mitchell MS, Mokyr MB, Goldwater DJ: Analysis and reversal of the inhibition of cytophilic antibody receptors produced by antibody. Cancer Res 35: 1121–1127, 1975.PubMedGoogle Scholar
  265. 265.
    Mitchell MS: Role of “suppressor” T lymphocytes in antibody-induced inhibition of cytophilic antibody receptors. Ann NY Acad Sci 276: 229–242, 1976.PubMedGoogle Scholar
  266. 266.
    Rao VS, Mokyr MB, Gershon RK, Mitchell MS: Specific T cell dependent, antigen-antibody mediated suppression of macrophages: Abrogation by nonspecifically stimulated T cells. J Immunol 118: 2117–2124, 1977.PubMedGoogle Scholar
  267. 267.
    Rao VS, Grodzicki RL, Mitchell MS: Specific in vivo inhibition of macrophage receptors for cytophilic antibody by soluble immune complexes. Cancer Res 39: 174–182, 1979.PubMedGoogle Scholar
  268. 268.
    Rao VS, Bennett JA, Shen FW, Gershon RK, Mitchell MS: Antigen-antibody complexes generate Lyt-1 inducers of suppressor cells. J Immunol 125: 63–67, 1980.PubMedGoogle Scholar
  269. 269.
    Douvas GS, Kinsky RG, Duc HT, Voisin GA: Suppressor cells as an agent of immune facilitation. II. Adoptive transfer of passively induced enhancement of allografted tumors. Cell Immunol 68: 389–401, 1982.PubMedGoogle Scholar
  270. 270.
    Stelzer GT, Wallace JH: Suppressor cells in mice bearing the B16 melanoma. Proc Am Assoc Cancer Res 18: 68, 1977.Google Scholar
  271. 271.
    Stelzer GT, Wallace JH: Characterization of suppressor cells in mice with a transplantable malignant melanoma. Oncology 37: 397–405, 1980.PubMedGoogle Scholar
  272. 272.
    Stelzer GT, Shellhaas JL, Wallace JH: The association of suppressor cells with mononuclear cell aggregates in spleens of tumor-bearing mice. Cell Immunol 56: 292–304, 1980.PubMedGoogle Scholar
  273. 273.
    Meruelo D, Flieger N, Smith D, McDevitt HO: In vivo or in vitro treatments with anti-I-J alloantisera abolish immunity to AKR leukemia. Proc Nall Acad Sci USA 77: 2178–2182, 1980.Google Scholar
  274. 274.
    Fulton AM, Levy JG: The possible role of prostaglandins in mediating immune suppression by nonspecific T suppressor cells. Cell Immunol 52: 29–37, 1980.PubMedGoogle Scholar
  275. 275.
    Howie S, McBride WH: Tumor-specific T helper activity can be abrogated by two distinct suppressor cell mechanisms. Eur J Immunol 12: 671–675, 1982.PubMedGoogle Scholar
  276. 276.
    Payelle B, Lespinats G, Tlouzeau S: Role of T suppressor cells in the cycling of the immune response against a murine fibrosarcoma. Int J Cancer 34: 95–100, 1984.PubMedGoogle Scholar
  277. 277.
    Levy JG, Maier T, Kilburn DG: Further characterization of thymic suppressor cells and a factor that suppress the generation of cells cytotoxic for a syngeneic tumor in DBA/2 mice. J Immunol 122: 766–771, 1979.PubMedGoogle Scholar
  278. 278.
    Maier T, Levy JG, Kilburn DG: The Lyt phenotype of cells involved in the cytotoxic response to syngeneic tumor and of tumor-specific suppressor cells. Cell Immunol 56: 392–399, 1980.PubMedGoogle Scholar
  279. 279.
    Haubeck H-D, Kölsch E: Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. III. Induction of specific T suppressor cells to the BALB/c plasmacytoma ADJ-PC-5 during early stages of tumorigenesis. Immunology 47: 503–510, 1982.PubMedGoogle Scholar
  280. 280.
    Bluestone JA, Lopez C: Suppression of the immune response in tumor-bearing mice. I. Response to virus-producing tumor cells and non-virus-producing tumor cells. J Nall Cancer Inst 63: 1215–1220, 1979.Google Scholar
  281. 281.
    Lynch RG, Rohrer JW, Odermatt B, Gegel HM, Autry JR, Hoover RG: Immunoregulation of murine myeloma cell growth and differentiation: A monoclonal model of B cell differentiation. Immunol Rev 48: 45–80, 1979.PubMedGoogle Scholar
  282. 282.
    Rohrer JW, Odermatt B, Lynch RG: Immunoregulation of murine myeloma: Isologous immunization with M315 induces idiotype-specific T cells that suppress IgA secretion by MOPC-315 cells in vivo. J Immunol 122: 2011–2019, 1979.PubMedGoogle Scholar
  283. 283.
    Behforouz N, Eardley DD, Cerny J: “Nonspecific” immunoenhancing T cells in tumor-bearing mice include anti-idiotypic subsets. J Immunol 131: 2576–2579, 1983.PubMedGoogle Scholar
  284. 284.
    Koppi TA, Halliday WJ, McKenzie FC: Regulation of cell-mediated immunologic reactivity to Moloney murine sarcoma virus-induced tumors. II. Nature of blocking and unblocking factors in serum. J Natl Cancer Inst 66: 1097–1102, 1981.PubMedGoogle Scholar
  285. 285.
    Fulton AM, Levy JG: The induction of nonspecific T suppressor lymphocytes by prostaglandin E,. Cell Immunol 59: 54–60, 1981.PubMedGoogle Scholar
  286. 286.
    Eardley DD, Gershon RK: Induction of specific suppressor T cells in vitro. J Immunol 117: 313–318, 1976.PubMedGoogle Scholar
  287. 287.
    Gershon RK, Eardley DD, Naidorf KF, Ptak W: The hermaphrocyte: A suppressor-helper T cell. Cold Spring Harbor Symp Quant Biol 41: 85–91, 1976.Google Scholar
  288. 288.
    Rohrer JW, Odermatt B, Lynch RG: Idiotype-specific suppression of MOPC-315 IgA secretion in vivo: Reversible blockade of secretory myeloma cells by soluble mediators. J Immunol 121: 1799–1807, 1978.PubMedGoogle Scholar
  289. 289.
    Milburn GL, Lynch RG: Immunoregulation of murine myeloma in vitro. II. Suppression of MOPC-315 immunoglobulin secretion and synthesis by idiotypespecific suppressor T cells. J Exp Med 155: 852–861, 1982.PubMedGoogle Scholar
  290. 290.
    Abbas AK, Takoki M, Greene MI: T lymphocyte-mediated suppression of myeloma function in vitro. IV. Generation of effector suppressor cells specific for myeloma idiotypes. J Exp Med 155: 1216–1221, 1982.PubMedGoogle Scholar
  291. 291.
    Argyris BF: Factors affecting suppressor cell activity in tumor allosensitized mice. J Natl Cancer Inst 64: 959–966, 1980.PubMedGoogle Scholar
  292. 292.
    Argyris BF: Suppressor factor from tumor-allosensitized spleen cells-its effect on in vitro proliferation of tumor cells and in vivo skin allograft survival. Cell Immunol 57: 62–72, 1981.PubMedGoogle Scholar
  293. 293.
    Tilkin AF, Gomard E, Begue B, Levy J-P: T cells from naive mice suppress the in vitro cytotoxic response against endogenous Gross virus-induced tumor cells. J Immunol 132: 520–526, 1984.PubMedGoogle Scholar
  294. 294.
    Subramanian C, Yu S, McKhann CF: Soluble suppressor factor from the spleens of tumor-bearing mice. Fed Proc 36: 1274, 1977.Google Scholar
  295. 295.
    Cihak J, Ziegler HW, Kölsch E: Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. I. Analysis of immune parameters involved. Immunology 43: 133–143, 1981.PubMedGoogle Scholar
  296. 296.
    Cihak J, Ziegler HW, Kölsch E: Regulation of immune responses against the syngeneic ADJ-PC-5 plasmacytoma in BALB/c mice. II. Suppression of T cell cytotoxicity by pretreatment of mice with subimmunogenic doses of tumour cells. Immunology 43: 145–152, 1981.PubMedGoogle Scholar
  297. 297.
    Nordlund JJ, Ackles A, Gershon RK: Quantitative factors which determine the effect of the immune response on the growth rate of the Cloudman melanoma in the DBA/2 mice. Cell Immunol 56: 258–272, 1980.PubMedGoogle Scholar
  298. 298.
    Argyris BF: Suppressor cells in the spleen of tumor-allosensitized mice. Cancer Res 37: 3390–3399, 1977.PubMedGoogle Scholar
  299. 299.
    Argyris BF, DeLustro F: Immunologic unresponsiveness of mouse spleen sensitized to allogeneic tumors. Cell Immunol 28: 390–403, 1977.PubMedGoogle Scholar
  300. 300.
    Argyris BF: Suppressor activity in the spleen of neonatal mice. Cell Immunol 36: 354–362, 1978.PubMedGoogle Scholar
  301. 301.
    Argyris BF, Cotellessa A: Adsorption of suppressor cell activity on mouse macrophage monolayers. Transplantation 28: 372–376, 1979.PubMedGoogle Scholar
  302. 302.
    Zografos-Miller LE, Argyris BF: Further characterisation of macrophage adsorption of suppressor cell activity from tumor-allosensitised spleen. Transplantation 35: 593–600, 1983.PubMedGoogle Scholar
  303. 303.
    Kinsky RG, Duc HT, Chaouat G, Voisin GA: Involvement of suppressor cells in active enhancement of allografted tumors. In vivo (adoptive transfer) and in vitro (MLR) evaluation. Synergy with enhancing antibodies. Cell Immunol 58:107–123, 1981.PubMedGoogle Scholar
  304. 304.
    Chiu KM, Faanes RB, Choi YS: Activation of specific suppressor cells with heat-treated allogeneic tumor cells. Cell Immunol 49: 283–292, 1980.PubMedGoogle Scholar
  305. 305.
    Rich SS, Rich RR: Regulatory mechanisms in cell-mediated immune responses. I. Regulation of mixed lymphocyte reactions by alloantigen-activated thymus-derived lymphocytes. J Exp Med 140: 1588–1603, 1974.PubMedGoogle Scholar
  306. 306.
    Argyris BF: Activation of suppressor cells by syngeneic tumor transplants in mice. Cancer Res 38: 1269–1273, 1978.PubMedGoogle Scholar
  307. 307.
    Russel PS, Chase CM, Burton RC: Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients. J Immunol 130: 951–957, 1983.Google Scholar
  308. 308.
    Bluestone JA, Lopez C, Hurtenbach U: Mixed lymphocyte reactivity in spleen cells from F-9 tumor bearing mice. I. Suppressor cell induction and characterization. Cell Immunol 62: 334–340, 1981.PubMedGoogle Scholar
  309. 309.
    Hurtenbach U, Bennett D, Bluestone JA: Mixed lymphocyte reactivity in spleen cells from F-9 tumor-bearing mice. II. Functional cross-reactivity between F-9 cells and testicular cells. Cell Immunol 62: 341–349, 1981.PubMedGoogle Scholar
  310. 310.
    Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN: Myeloma proteins as tumor specific transplantation antigens. Proc Natl Acad Sci USA 69: 1540–1544, 1972.PubMedGoogle Scholar
  311. 311.
    Abbas AK, Perry LL, Bach BA, Greene MI: Idiotype-specific T cells immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotype determinants. J Immunol 124: 1160–1166, 1980.PubMedGoogle Scholar
  312. 312.
    Flood PM, Philipps C, Taupier MN, Schreiber H: Regulation of myeloma growth in vitro by idiotype-specific T lymphocytes. J Immunol 124: 424–430, 1980.PubMedGoogle Scholar
  313. 313.
    Abbas AK, Burakoff SJ, Gefter ML, Greene MI: T lymphocyte-mediated suppression of myeloma function in vitro. III. Regulation of antibody production in hybrid myeloma cells by T lymphocytes. J Exp Med 152: 969–978, 1980.PubMedGoogle Scholar
  314. 314.
    Hoover RG, Dieckgraefe BK, Lake J, Kemp JD, Lynch RG: Lymphocyte surface membrane immunoglobulin in myeloma. III. IgA plasmacytomas induce large numbers of circulating, adult-thymectomy sensitive, theta positive, Lyt-12+ lymphocytes with IgA-Fc receptors. J Immunol 129: 2329–2331, 1982.PubMedGoogle Scholar
  315. 315.
    Moroni C, Schumann G: Are endogenous C-type viruses involved in the immune system? Nature 269: 600–601, 1977.PubMedGoogle Scholar
  316. 316.
    Wecker E, Schimpl A, Hünig T: Expresion of MuLV gp71-like antigen in normal mouse spleen cells induced by antigenic stimulation. Nature 269: 598–600, 1977.PubMedGoogle Scholar
  317. 317.
    Schumann G, Moroni C: Immunosuppressive activity of antibody directed against endogenous C-type virus interferes with early events of the immune response. J Immunol 120: 1913–1916, 1978.PubMedGoogle Scholar
  318. 318.
    Staber FG, Schlfli E, Moroni C: Expression of endogenous C-type viral antigen on normal mouse haemopoietic stem cells. Nature 275: 669–671, 1978.PubMedGoogle Scholar
  319. 319.
    Abbas AK: Antigen and T lymphocyte mediated suppression of myeloma cells: Model systems for regulation of lymphocyte function. Immunol Rev 48: 245–264, 1979.PubMedGoogle Scholar
  320. 320.
    Rohrer JW, Kemp J, Gershon RK, Cantor H: Two T cells interact to effect idiotypespecific suppression of M315 secretion by MOPC-315 cells in vivo. J Supramolec Struc Suppl 5: 81, 1981.Google Scholar
  321. 321.
    Hoover RG, Lynch RG: Isotype-specific suppression of IgA: Suppression of IgA responses in BALB/c mice by Ta cells. J Immunol 130: 521–523, 1983.PubMedGoogle Scholar
  322. 322.
    Müller S, Hoover RG: T cells with Fc receptors in myeloma: Suppression of growth and secretion of MOPC-315 by Ta cells. J Immunol 134: 644–647, 1985.PubMedGoogle Scholar
  323. 323.
    Abbas AK: Immunologic regulation of lymphoid tumor cells: Model systems for lymphocyte function. Adv Immunol 32: 301–368, 1982.PubMedGoogle Scholar
  324. 324.
    Plater C, Debré P, Leclerc J-C: T-cell mediated immunity to oncornavirus-induced tumors. III. Specific and non-specific suppression in tumor-bearing mice. Eur J Immunol 11: 39–44, 1981.PubMedGoogle Scholar
  325. 325.
    Deutsch O, Devens B, Naor D: Immune responses to weakly immunogenic murineleukemia-virus-induced tumors. VII. Kinetic studies on various parameters of effects induced with suppressor cells. lsr J Med Sci 16: 530–537, 1980.Google Scholar
  326. 326.
    Frost P, Prete P, Kerbel R: Abrogation of the in vitro generation of the cytotoxic T-cell response to a murine tumor: The role of suppressor cells. Int J Cancer 30: 211–217, 1982.PubMedGoogle Scholar
  327. 327.
    Ullrich SE, Kripke ML: Mechanism in the suppression of tumor rejection produced in mice by repeated UV irradiation. J Immunol 133: 2786–2790, 1984.PubMedGoogle Scholar
  328. 328.
    Deutsch O, Devens B, Naor D: Immune responses to weakly immunogenic murineleukemia-virus-induced tumors. VIII. Characterization of suppressor cells. Isr J Med Sci 16: 538–544, 1980.PubMedGoogle Scholar
  329. 329.
    Glaser M: Regulation of specific cell-mediated cytotoxic response against SV-40induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice. J Exp Med 149: 774–779, 1979.PubMedGoogle Scholar
  330. 330.
    Colnaghi MI, Ménard S: Regulatory role of T suppressor cells on natural and induced humoral anti-tumor reactivity of C57B1/6J mice. Jlmmunol 124: 2530–2535, 1980.Google Scholar
  331. 331.
    Gautam SC, Deodhar SD: Presence of suppressor cells in spleen of mice bearing a weakly immunogenic syngeneic tumor. Cancer Res 39: 2945–2951, 1980.Google Scholar
  332. 332.
    Spellman CW, Daynes RA: Properties of ultraviolet light-induced suppressor lymphocytes within a syngeneic tumor system. Cell Immunol 36: 383–387, 1978.PubMedGoogle Scholar
  333. 333.
    Urbach F (ed): The Biologic Effects of Ultraviolet Radiation, p. 635. Oxford: Perga-mon, 1969.Google Scholar
  334. 334.
    National Research Council Committee on National Statistics. Environmental Impacts of Stratospheric Flight (NRC Climatic Impact Committee), p. 177. National Academy of Sciences, Washington DC, 1975.Google Scholar
  335. 335.
    Blum HF: Carrinogenesis by Ultraviolet Light. Princeton, NJ: Princeton Univ Press, 1959.Google Scholar
  336. 336.
    Zajdela F, Latarjet R: Inhibition of skin carcinogenesis in vivo by caffeine and other agents. Natl Cancer Inst Monogr 50: 133–140, 1978.PubMedGoogle Scholar
  337. 337.
    Kripke ML: Antigenicity of murine skin tumors induced by ultraviolet light. JNatl Cancer Inst 53: 1333–1336, 1974.Google Scholar
  338. 338.
    Kripke ML, Fisher MS: Immunologic parameters of ultraviolet carcinogenesis. J Natl Cancer Inst 57: 211–215, 1976.PubMedGoogle Scholar
  339. 339.
    Kripke ML: Latency histology and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 37: 1395–1400, 1977.PubMedGoogle Scholar
  340. 340.
    Daynes RA, Spellman CW, Woodward JG, Stewart DA: Studies into the transplantation biology of ultraviolet light-induced tumors. Transplantation 23: 343–348, 1977.PubMedGoogle Scholar
  341. 341.
    Spellman CW, Woodward JG, Daynes RA: Modification of immunological potential by ultraviolet radiation. I. Immune status of short-term UV-irradiated mice. Transplantation 24: 112–119, 1977.PubMedGoogle Scholar
  342. 342.
    Kripke ML, Lofgreen JS, Beard J, Jessup JM, Fisher MS: In vivo immune responses of mice during carcinogenesis by ultraviolet irradiation. J Natl Cancer Inst 59: 1227–1230, 1977.PubMedGoogle Scholar
  343. 343.
    Spellman CW, Daynes RA: Modification of immunological potential by ultraviolet radiation. II. Generation of suppressor cells in short-term UV-irradiated mice. Transplantation 24: 120–126, 1977.PubMedGoogle Scholar
  344. 344.
    Fortner GW, Kripke ML: In vitro reactivity of splenic lymphocytes from normal and UV-irradiated mice against syngeneic UV-induced tumors. J Immunol 118: 1483 1487, 1977.Google Scholar
  345. 345.
    Fisher MS, Kripke ML: Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis. Proc Natl Acad Sci USA 74: 1688–1692, 1977.PubMedGoogle Scholar
  346. 346.
    Norbury KC, Kripke ML, Budmen MB: In vitro reactivity of macrophages and lymphocytes from ultraviolet-irradiated mice. J Natl Cancer Inst 59: 1231–1237, 1977.PubMedGoogle Scholar
  347. 347.
    Daynes RA, Spellman CW: Evidence for the generation of suppressor cells by ultraviolet radiation. Cell Immunol 31: 182–187, 1977.PubMedGoogle Scholar
  348. 348.
    Fisher MS, Kripke ML: Further studies on the tumor specific suppressor cells induced by ultraviolet radiation. J lmmunol 121: 1139–1144, 1978.Google Scholar
  349. 349.
    Jessup JM, Hanna N, Palaszynski E, Kripke ML: Mechanisms of depressed reactivity to dinitrochlorobenzene and ultraviolet-induced tumors during ultraviolet carcinogenesis in BALB/c mice. Cell lmmunol 38: 105–115, 1978.Google Scholar
  350. 350.
    Spellman CW, Daynes RA: Ultraviolet light induced murine suppressor lymphocytes dictate specificity of anti-ultraviolet tumor immune responses. Cell Immunol 38: 25–34, 1978.PubMedGoogle Scholar
  351. 351.
    Fisher MS: A systemic effect of ultraviolet irradiation and its relationship to tumor immunity. Nati Cancer Inst Monogr 50: 185–188, 1978.Google Scholar
  352. 352.
    Thorn RM: Specific inhibition of cytotoxic memory cells produced against UV-induced tumors in UV-irradiated mice. J lmmunol 121: 1920–1926, 1978.Google Scholar
  353. 353.
    Daynes RA, Schmitt MK, Roberts LK, Spellman CW: Phenotypic and physical characteristics of the lymphoid cells involved in the immunity to syngeneic UV-induced tumors. J Immunol 122: 2458–2464, 1979.PubMedGoogle Scholar
  354. 354.
    Kripke ML, Thorn RM, Lill PH, Civin CI, Pazmino NH, Fisher MS: Further characterization of immunological unresponsiveness induced in mice by ultraviolet radiation: Growth and induction of nonultraviolet-induced tumors in ultraviolet-irradiated mice. Transplantation 28: 212–217, 1979.PubMedGoogle Scholar
  355. 355.
    DeFabo EC, Kripke ML: Dose-response characteristics of immunologic unresponsiveness to UV-induced tumors produced by UV irradiation of mice. Photochem Photobiol 30: 385–390, 1979.PubMedGoogle Scholar
  356. 356.
    Roberts LK, Daynes RA: Modification of the immunogenic properties of chemically induced tumors arising in hosts treated concomitantly with ultraviolet light. J Immunol 125: 438–447, 1980.PubMedGoogle Scholar
  357. 357.
    Roberts LK, Spellman CW, Daynes RA: Modulation of immunoregulatory responses directed towards various tumor antigens within hosts possessing distinct immunologic potentials. J Immunol 125: 663–672, 1980.PubMedGoogle Scholar
  358. 358.
    Thorn RM, Fisher MS, Kripke ML: Further characterization of immunological unresponsiveness induced in mice by ultraviolet radiation. II. Studies on the origin and activity of ultraviolet-induced suppressor lymphocytes. Transplantation 31: 129–133, 1981.PubMedGoogle Scholar
  359. 359.
    Roberts LK, Lynch DH, Daynes RA: Evidence for two functionally distinct cross reactive tumor antigens associated with ultraviolet light and chemically induced tumors. Transplantation 33: 352–360, 1982.PubMedGoogle Scholar
  360. 360.
    Fisher MS, Kripke ML: Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. Science 216: 1133–1134, 1982.PubMedGoogle Scholar
  361. 361.
    Roberts LK, Spellman CW, Warner NL: Establishment of a continuous T cell line capable of suppressing anti-tumor immune responses in vivo. J Immunol 131: 514–519, 1983.PubMedGoogle Scholar
  362. 362.
    Fisher MS, Kripke ML, Chan GL: Antigenic similarity between cells transformed by ultraviolet radiation in vitro and in vivo. Science 223: 593–594, 1984.PubMedGoogle Scholar
  363. 363.
    Kripke ML: Immunologic mechanisms in UV radiation carcinogenesis. Adv Cancer Res 34: 69–106, 1981.PubMedGoogle Scholar
  364. 364.
    Daynes RA, Bernhard EJ, Gurish MF, Lynch DH: Experimental photoimmunology: Immunologic ramifications of UV-induced carcinogenesis. J Invest Dermatol 77: 77–85, 1981.PubMedGoogle Scholar
  365. 365.
    Daynes RA, Gurish MF, Lynch DH, Spangrude GU: Biological consequences of acute and chronic UVR exposures. In Parrish JA (ed): The Effect of Ultraviolet Radiation on the Immune System, pp. 209–228. Skillman, NJ: Johnson and Johnson Baby Products Co., 1983.Google Scholar
  366. 366.
    Kripke ML: Immunological unresponsiveness induced by ultraviolet radiation. Immunol Rev 80: 87–102, 1984.PubMedGoogle Scholar
  367. 367.
    Rusch HP, Baumann CA: Tumor production in mice with ultraviolet irradiation. Am J Cancer 35: 55–62, 1939.Google Scholar
  368. 368.
    Greene MI, Sy MS, Kripke M, Benacerraf B: Impairment of antigen-presenting cell function by ultraviolet radiation. Proc Natl Acad Sci USA 76: 6591–6595, 1979.PubMedGoogle Scholar
  369. 369.
    Toews GB, Bergstresser PR, Streilein JW, Sullivan S: Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 124: 445–453, 1980.PubMedGoogle Scholar
  370. 370.
    Granstein RD, Lowy A, Greene MI: Epidermal antigen-presenting cells in activation of suppression: Identification of a new functional type of ultraviolet radiation-resistant epidermal cell. J Immunol 132: 563–565, 1984.PubMedGoogle Scholar
  371. 371.
    Yefenof E, Meidav A, Kedar E: In vitro generation of cytotoxic lymphocytes against radiation and radiation leukemia virus-induced tumors. III. Suppression of antitumor immunity in vitro by lymphocytes of mice undergoing radiation leukemia virus-induced leukemogenesis. J Exp Med 152: 1473–1483, 1980.PubMedGoogle Scholar
  372. 372.
    Yefenof E, Zilcha D: High and low leukemogenic variants of the radiation leukemia virus (RadLV) differ in ability to induce tumor-specific immune suppression. Int J Cancer 30: 355–359, 1982.PubMedGoogle Scholar
  373. 373.
    Yefenof E, Ben David Y, Kotler M: High and low leukemogenic variants of the radiation leukemia virus (RadLV): Immunogenic, suppressive and genetic properties in relation to leukemogenic activity. Int J Cancer 34: 875–882, 1984.PubMedGoogle Scholar
  374. 374.
    Haran-Ghera N: Spontaneous and induced preleukemia cells in C57B1/6 mice: Brief communication. J Natl Cancer Inst 60: 707–710, 1978.PubMedGoogle Scholar
  375. 375.
    Haran-Ghera N, Peled A: Induction of leukemia in mice by irradiation and radiation leukemia virus variants. Adv Cancer Res 30: 45–87, 1979.PubMedGoogle Scholar
  376. 376.
    Galili N, Naor D, Asjö B, Klein G: Induction of immune responsiveness in a genetically low-responsive tumor-host combination by chemical modification of the immunogen. Eur J Immunol 6: 473–476, 1976.PubMedGoogle Scholar
  377. 377.
    Galili N, Devens B, Naor D, Becker S, Klein E: Immune responses to weakly immunogenic virally-induced tumors. I. Overcoming low responsiveness by priming mice with a syngeneic in vitro tumor line or allogeneic cross-reactive tumor. Eur J Immunol 8: 17–22, 1978.PubMedGoogle Scholar
  378. 378.
    Devens B, Galili N, Deutsch O, Naor D, Klein E: Immune responses to weakly immunogenic virally-induced tumors. II. Suppressive effects of the in vivo carried tumor YAC. Eur J Immunol 8: 573–578, 1978.PubMedGoogle Scholar
  379. 379.
    Devens B, Naor D: Immune responses to weakly immunogenic tumors. VI. Comparison of the immune response of the hybrid to the immune responses of the parent reveals “hybrid responsiveness” effect. J Immunol 125: 988–994, 1980.PubMedGoogle Scholar
  380. 380.
    Devens B, Deutsch O, Avraham Y, Naor D: Immune response to weakly immunogenic virally induced tumors. IX. Mice injected with the in vitro variant of YAC tumor (YAC-L) resist lethal doses of the tumorigenic YAC cells. Immunobiology 159: 432–443, 1981.PubMedGoogle Scholar
  381. 381.
    Klein BY, Devens B, Deutsch O, Ahituv A, Frenkel S, Kobrin BJ, Naor D: Isolation of immunogenic and suppressogenic determinants of the nonimmunogenic YAC tumor and the change in its immunogenic repertoire after in vitro cultivation. Transplant Proc 13: 790–797, 1981.PubMedGoogle Scholar
  382. 382.
    Sharon R, Klein BY, Avraham Y, Kaner N, Tarcic N, Naor D: The change of the immunogenic repertoire of YAC tumor cells after in vitro cultivation. In Resch K, Kirchner H (eds): Mechanisms of Lymphocyte Activation, pp. 636–639. Amsterdam: Elsevier/North Holland, 1981.Google Scholar
  383. 383.
    McCoy JL, Fefer A, Glynn JP: Comparative studies on the induction of transplantation resistance in BALB/c and C57B1/6 mice in three murine leukemia systems. Cancer Res 27: 1743–1748, 1967.PubMedGoogle Scholar
  384. 384.
    Kit S, Kurimura T, Dubbs DR: Transplantable mouse tumor line induced by injection of SV-40-transformed mouse kidney cells. Int J Cancer 4: 384–392, 1969.PubMedGoogle Scholar
  385. 385.
    Nordlund JJ, Cone RE, Ackles A, Gershon R: Surface proteins on Cloudman melanoma cells. Cell Immunol 56: 273–285, 1980.PubMedGoogle Scholar
  386. 386.
    Fuji H: Immunomodulation of host resistance by tumor variants. Transplant Proc 16: 460–462, 1984.PubMedGoogle Scholar
  387. 387.
    Pierres M, Germain RN, Dorf ME, Benacerraf B: In vivo effects of anti-Ia alloantisera. I. Elimination of specific suppression by in vivo administration of antisera specific for I-J controlled determinants. J Exp Med 147: 656–666, 1978.PubMedGoogle Scholar
  388. 388.
    Perry LL, Kripke ML, Benacerraf B, Dorf ME, Greene MI: Regulation of the immune response to tumor antigen. VIII. The effects of host specific anti-I-J antibodies on the immune response to tumors of different origin. Cell Immunol 51: 349–359, 1980.PubMedGoogle Scholar
  389. 389.
    Drebin JA, Waltenbaugh C, Schatten S, Benacerraf B, Greene MI: Inhibition of tumor growth by monoclonal anti-I-J antibodies. J Immunol 130: 506–509, 1983.PubMedGoogle Scholar
  390. 390.
    Granstein RD, Parrish JA, McAuliffe DJ, Waltenbaugh C, Greene MI: Immunologic inhibition of ultraviolet radiation-induced tumor suppressor cell activity. Science 224: 615–617, 1984.PubMedGoogle Scholar
  391. 391.
    Tada T, Takemori T, Okumura K, Nonaka M, Tokuhisa T: Two distinct types of helper T cells involved in the secondary antibody response: Independent and synergistic effects of la-and la+ helper T cells. J Exp Med 147: 446–458, 1978.PubMedGoogle Scholar
  392. 392.
    Greene MI, Perry LL, Benacerraf B: Regulation of the immune response to tumor antigen. V. Modulation of suppressor T cell activity in vivo. Am J Pathol 95: 159–169, 1979.PubMedGoogle Scholar
  393. 393.
    Malave I, Blanca I, Fuji H: Influence of inoculation site on development of the Lewis lung carcinoma and suppressor cell activity in syngeneic mice. J Natl Cancer Inst 62: 83–88, 1979.PubMedGoogle Scholar
  394. 394.
    Fernandez-Cruz E, Halliburton B, Feldman JD: In vivo elimination by specific effector cells of an established syngeneic rat Moloney virus-induced sarcoma. J Immunol 123: 1772–1777, 1979.PubMedGoogle Scholar
  395. 395.
    Kedar E, Chriqui-Zeira E, Kyriazis AP: Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes. J Biol Resp Modif 3: 517–526, 1984.Google Scholar
  396. 396.
    North RJ: The murine antitumor immune response and its therapeutic manipulation. Adv Immunol 35: 89–155, 1984.PubMedGoogle Scholar
  397. 397.
    Berendt MJ, North RI: T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151: 69–80, 1980.PubMedGoogle Scholar
  398. 398.
    Dye ES, North RJ: T-cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J Exp Med 154: 1033–1042, 1981.PubMedGoogle Scholar
  399. 399.
    North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor cells. J Exp Med 155: 1063–1074, 1982.PubMedGoogle Scholar
  400. 400.
    Mills CD, North RJ: Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med 157: 1448–1460, 1983.PubMedGoogle Scholar
  401. 401.
    Dye ES, North RJ: Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors. J Leukocyte Biol 36: 27–37, 1984.PubMedGoogle Scholar
  402. 402.
    North RJ: ry-Irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother 16:175–181, 1984.PubMedGoogle Scholar
  403. 403.
    North RJ, Bursuker I: Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2 suppressor T cells down-regulate the generation of Ly-12+ effector T cells. J Exp Med 159: 1295–1311, 1984.PubMedGoogle Scholar
  404. 404.
    North RJ, Bursuker I: T cell-mediated suppression of the concomitant antitumor immune response as an example of transplantation tolerance. Transplant Proc 16: 463–469, 1984.PubMedGoogle Scholar
  405. 405.
    Bursuker I, North RJ: Generation and decay of the immune response to a progressive fibrosarcoma. II. Failure to demonstrate post-excision immunity after the onset of T cell mediated suppression of immunity. J Exp Med 159: 1312–1321, 1984.PubMedGoogle Scholar
  406. 406.
    North RI, Dye ES, Mills CD: T cell mediated negative regulation of concomitant antitumor immunity as an obstacle to adoptive immunotherapy of established tumors. In Fefer A, Goldstein A (eds): The Potential Role of T Cells in Cancer Therapy, pp. 65–76. New York: Raven Press, 1982.Google Scholar
  407. 407.
    North RJ: The generation and down regulation of the antitumor immune response: Ly-1+ suppressor T cells abridge the generation of Ly-2+ effector T cells. Prog Immunol 5: 1239–1251, 1983.Google Scholar
  408. 408.
    North RJ: Models of adoptive T-cell-mediated regression of established tumors. Contemp Topics Immunobiol 13: 243–257, 1984.Google Scholar
  409. 409.
    Berendt MJ, North RI, Kirstein DP: The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med 148: 1550–1559, 1978.PubMedGoogle Scholar
  410. 410.
    Bonventre PF, Nickol AD, Ball EJ, Michael JG, Bubel HC: Development of protective immunity against bacterial and viral infections in tumor-bearing mice coincident with suppression of tumor immunity. J Reticuloendothel Soc 32: 25–35, 1982.PubMedGoogle Scholar
  411. 411.
    Gillespie GY, Hansen CB, Russell SW: Resurgence of killing and in vivo protection mediated by lymphocytes cultured from lymph nodes draining Moloney sarcomas. Br J Cancer 38: 365–374, 1978.PubMedGoogle Scholar
  412. 412.
    Hodes RJ, Hathcock KS: In vitro generation of suppressor cell activity: Suppression of an in vitro induction of cell-mediated cytotoxicity. J Immunol 116: 167–177, 1976.PubMedGoogle Scholar
  413. 413.
    Chiorazzi N, Fox DA, Katz DH: Hapten-specific IgE antibody responses in mice. VI. Selective enhancement of IgE antibody production by low doses of x-irradiation and by cyclophosphamide. J Immunol 117: 1629–1637, 1976.PubMedGoogle Scholar
  414. 414.
    Parker D, Dwyer JM, Turk JL: The effect of cyclophosphamide and role of suppressor cells in the desensitization of delayed hypersensitivity. Immunology 43: 191–196, 1981.PubMedGoogle Scholar
  415. 415.
    Tarcic N, Naor D: Delayed-type hypersensitivity induced in immunodeficient mice with syngeneic modified self antigens: A suggestive model of autoimmune response. Eur J Immunol 12: 961–966, 1982.PubMedGoogle Scholar
  416. 416.
    Fefer A, Einstein AB, Cheever MA: Adoptive chemoimmunotherapy of cancer in animals: A review of results, principles and problems. Ann NY Acad Sci 277: 492–504, 1976.PubMedGoogle Scholar
  417. 417.
    Greenberg PD, Cheever MA, Fefer A: Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2 lymphocytes. J Exp Med 154: 952–963, 1981.PubMedGoogle Scholar
  418. 418.
    Greenberg PD, Cheever MA: Treatment of disseminated leukemia with cyclophosphamide and immune cells: Tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol 133: 3401–3407, 1984.PubMedGoogle Scholar
  419. 419.
    Evans R: Phenotypes associated with tumor rejection mediated by cyclophosphamide and syngeneic tumor-sensitized T lymphocytes: Potential mechanisms of action. Int J Cancer 33: 381–388, 1984.PubMedGoogle Scholar
  420. 420.
    Kimura H, Yamaguchi Y, Fujisawa T: Specific immunotherapy combined with whole body irradiation of BALB/c mice bearing Moloney murine sarcoma virus-induced primary tumors. Gann (Tokyo) 73: 446–453, 1982.Google Scholar
  421. 421.
    Dennis J, Frost P, Kerbel RS: Syngeneic CTL responses of allogeneic magnitude induced against membrane mutant sublines of a poorly immunogenic tumor. Immunobiology 159: 185, 1981.Google Scholar
  422. 422.
    Gorelik E: Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res 39: 71–120, 1983.PubMedGoogle Scholar
  423. 423.
    Ehrlich P: Experimentelle carcinomstudien an mäusen. In Ehrlich P (ed): Arbeiten aus dem Königlichen Institut fir Experimentelle Therapie zu Frankfurt/A.M., p. 77. Jena: Fisher, 1906.Google Scholar
  424. 424.
    Gershon RK, Carter R, Kondo K: On concomitant immunity in tumour-bearing hamsters. Nature 213: 674–676, 1967.PubMedGoogle Scholar
  425. 425.
    Gershon RK: Regulation of concomitant immunity. Activation of suppressor cells by tumor excision. Isr J Med Sci 10: 1012–1023, 1974.Google Scholar
  426. 426.
    North RJ, Kirstein DP: T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of non-specific immunity to unrelated tumors and bacterial parasites. J Exp Med 145: 275–292, 1977.PubMedGoogle Scholar
  427. 427.
    Nossal GJV: The case history of Mr. T.I.: Terminal patient or still curable? Immunol Today 1:5–9, 1980.Google Scholar
  428. 428.
    Hewitt HB: Animal tumor models and their relevance to human tumor immunology. J Biol Resp Modif 1: 107, 1982.Google Scholar
  429. 429.
    Terry WD: Concluding remarks. In Terry WD, Windhorst D (eds): Immunotherapy of Cancer, pp. 669–671. New York: Raven Press, 1978.Google Scholar
  430. 430.
    Dye ES, North RI, Mills CD: Mechanisms of anit-tumor action of Corynebacterium parvum. I. Potentiated tumor specific immunity and its therapeutic limitations. J Exp Med 154: 609–620, 1981.PubMedGoogle Scholar
  431. 431.
    Mills CD, North RJ, Dye ES: Mechanisms of anti-tumor action of Corynebacterium parvum. II. Potentiated cytolytic T cell response and its tumor-induced suppression. J Exp Med 154: 621–630, 1981.PubMedGoogle Scholar
  432. 432.
    Fernandez-Cruz E, Woda BA, Feldman JD: Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med 152: 823–841, 1980.PubMedGoogle Scholar
  433. 433.
    Fernandez-Cruz E, Gilman SC, Feldman JD: Altered levels of mononuclear leukocytes in tumor-bearing rats: Decrease of helper T lymphocytes and increase of suppressor cells. J Immunol 129: 1324–1328, 1982.PubMedGoogle Scholar
  434. 434.
    Matossian-Rogers A, Rogers P: Tumour-induced changes in murine lymphocyte profiles. Br J Cancer 46: 452–456, 1982.PubMedGoogle Scholar
  435. 435.
    Leclerc J-C, Plater C, Connan F, Debré P: T-cell mediated immunity to oncornavirus-induced tumors. IV. Preliminary evidence for a specific suppression of anti-Moloney cell-mediated immune response by autoimmune T cells. Eur J Immunol 11: 45–47, 1981.PubMedGoogle Scholar
  436. 436.
    Flood PM, Kripke ML, Rowley DA, Schreiber H: Suppression of tumor rejection by autologous anti-idiotype immunity. Proc Natl Acad Sci USA 77: 2209–2213, 1980.PubMedGoogle Scholar
  437. 437.
    Tilkin AF, Schaaf-Lafontaine N, Van Acker A, Boccadoro M, Urbain J: Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor cells. Proc Natl Acad Sci USA 78: 1809–1812, 1981.PubMedGoogle Scholar
  438. 438.
    Huber SA, Bigi G, Lucas ZJ: Cycling of immune responses to a syngeneic murine mammary adenocarcinoma. Cancer Res 40: 3484–3490, 1980.PubMedGoogle Scholar
  439. 439.
    Huber SA, Bigi G, Lucas ZJ: Tumor-specific suppressor cells induced by immunization with spleen cells from tumor-bearing animals. Cancer Res 40: 3477–3483, 1980.PubMedGoogle Scholar
  440. 440.
    Binz H, Meier B, Wigzell H: Induction or elimination of tumor specific immunity against a chemically-induced rat tumor using auto-anti-idiotypic immunity. Int J Cancer 29: 417–423, 1982.PubMedGoogle Scholar
  441. 441.
    Schaaf-Lafontaine N: Separation of lymphoid cells with a suppressor effect on the activity of cytotoxic cells in vitro during the growth of a syngeneic mouse tumour. Int J Cancer 21: 329–333, 1978.PubMedGoogle Scholar
  442. 442.
    Mitchison NA: Immunologic approach to cancer. Transplant Proc 2: 92–103, 1970.PubMedGoogle Scholar
  443. 443.
    Yamamoto H, Hamaoka T, Yoshizawa M, Kuroki M, Kitagawa M: Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. I. Detection and characterization of hapten-reactive suppressor T cell reactivity in mice immunized with hapten-isologous protein conjugate. J Exp Med 146: 74–90, 1977.PubMedGoogle Scholar
  444. 444.
    Hamaoka T, Yoshizawa M, Yamamoto H, Kuroki M, Kitagawa M: Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. II. Selective inactivation of hapten-reactive suppressor T cells by hapten-nonimmunogenic copolymers of D-amino acids, and its application to the study of suppressor T-cell effect on helper T-cell development. J Exp Med 146: 91–106, 1977.PubMedGoogle Scholar
  445. 445.
    Hamaoka T, Fujiwara H, Teshima K, Aoki H, Yamamoto H, Kitagawa M: Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor specific killer T lymphocyte activities by suppressor T cell depleted hapten-reactive T lymphocytes. J Exp Med 149: 185–199, 1979.PubMedGoogle Scholar
  446. 446.
    Fujiwara H, Hamaoka T, Shearer GM, Yamamoto H, Terry WD: The augmentation of in vitro and in vivo tumor specific T-cell-mediated immunity by amplifier T lymphocytes. J Immunol 124: 863–869, 1980.PubMedGoogle Scholar
  447. 447.
    Takatsu K, Hamaoka T, Tominaga A, Kanamasa Y: Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells. J Immunol 125: 2367–2373, 1980.PubMedGoogle Scholar
  448. 448.
    Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T: Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression. Jlmmunol 132: 1571–1577, 1984.Google Scholar
  449. 449.
    Fujiwara H, Aoki H, Yoshioka T, Tomita S, Ikegami R, Hamaoka T: Establishment of a tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to the autochthonous tumor system. J Immunol 133: 509–514, 1984.PubMedGoogle Scholar
  450. 450.
    Hamaoka T, Fujiwara H; Augmented induction of tumor-specific immunity by T-T cell interaction and its application to active immunotherapy. Prog Immunol 5: 1253–1268, 1983.Google Scholar
  451. 451.
    Goodnight JE Jr, Morton DL: Immunotherapy for malignant disease. Annu Rev Med 29: 231–283, 1978.PubMedGoogle Scholar
  452. 452.
    Terashima M, Takeichi N, Suzuki K, Itaya T, Gotohda E, Kobayashi H: Enhanced immunogenicity of xenogenized tumor cells in rats pretreated with cyclophosphamide. Tohoku J Exp Med 132: 355–361, 1980.Google Scholar
  453. 453.
    Mathe G, Halle-Pannenko O, Bourut C: Effectiveness of murine leukemia chemotherapy according to the immune state: Reconsideration of correlations between chemotherapy, tumour cell killing and survival time. Recent Results Cancer Res 62: 9–12, 1977.PubMedGoogle Scholar
  454. 454.
    Tarnowski G, Faanes RB, Ralph P, Williams N: Suppression and restoration of cytotoxic T-cell activity during chemotherapy of a mouse T-cell lymphoma and a macrophage tumor. Cancer Res 38: 4540–4545, 1978.PubMedGoogle Scholar
  455. 455.
    Goto M, Mitsuoka A, Sugiyama M, Kitano M: Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs: A common biological phenomenon. J Exp Med 154: 204–209, 1981.PubMedGoogle Scholar
  456. 456.
    Ishizuka M, Takeuchi T, Masuda T, Fukasawa S, Umezawa H: Enhancement of immune responses and possible inhibition of suppressor cells by aclacinomycin A. J Antibiot 34: 331–340, 1980.Google Scholar
  457. 457.
    Ehrke MJ, Ryoyama K, Cohen SA: Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res 44: 2497–2504, 1984.PubMedGoogle Scholar
  458. 458.
    Sendo F, Miyake T, Fuyama S, Arai S: Spontaneous regression of syngeneic transplanted tumor in rats pretreated with the antileukemia drug busulphan. J Natl Cancer Inst 60: 385–389, 1978.PubMedGoogle Scholar
  459. 459.
    Mizushima Y, Sendo F, Miyake T, Kobayashi H: Augmentation of specific cell-mediated immune responses to tumor cells in tumor bearing rats pretreated with the anti-leukemia drug busulphan. J Natl Cancer Inst 66: 659–665, 1981.PubMedGoogle Scholar
  460. 460.
    Mizushima Y, Sendo F, Takeichi N, Hosohawa M, Kobayashi H: Enhancement of antitumor transplantation resistance in rats by appropriately timed administration of busulphan. Cancer Res 41: 2917–2921, 1981.PubMedGoogle Scholar
  461. 461.
    Hosokawa M, Suzuki Y, Takimoto M, Kiyoshi M, Mizushima Y, Kobayashi H: Elimination of suppressor cells by bleomycin for augmentation of antitumor resistance in WKA rats immunized with irradiated tumor cells, Cancer Res, in press.Google Scholar
  462. 462.
    Askenase PW, Hayden BJ, Gershon RK: Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J Exp Med 141: 697–702, 1975.PubMedGoogle Scholar
  463. 463.
    Mitsuoka A, Baba M, Morikawa S: Enhancement of delayed hypersensitivity by depletion of suppressor T cells with cyclophosphamide in mice. Nature 262: 77–78, 1976.PubMedGoogle Scholar
  464. 464.
    Röllinghoff M, Starzinski-Powitz A, Pfizenmaier K, Wagner H: Cyclophosphamidesensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J Exp Med 145: 455–459, 1977.PubMedGoogle Scholar
  465. 465.
    Hellström I, Hellström KE: Cyclophosphamide delays 3-methylcholanthrene sarcoma induction in mice. Nature 275: 129–130, 1978.PubMedGoogle Scholar
  466. 466.
    Nomi S, Pellis NR, Kahan BD: Retardation of postsurgical metastases with the use of extracted tumor-specific transplantation antigens and cyclophosphamide. J Natl Cancer Inst 73: 943–950, 1984.PubMedGoogle Scholar
  467. 467.
    Glaser M: Augmentation of specific immune response against a syngeneic SV40-induced sarcoma in mice by depletion of suppressor T cells with cyclophosphamide. Cell Immunol 48: 339–345, 1979.PubMedGoogle Scholar
  468. 468.
    Yu S, Lannin DR, Tsui-Collins AL, McKhann CF: Effect of cyclophosphamide on mice bearing methylcholanthrene-induced fibrosarcomas. Cancer Res 40: 2756–2761, 1980.PubMedGoogle Scholar
  469. 469.
    Nakajima H, Abe S, Masuko Y, Tsubouchi J, Yamazaki M, Mizuno D: Elimination of tumor-enhancing cells by cyclophosphamide and its relevance to cyclophosphamide therapy of a murine mammary tumor. Gann (Tokyo) 72: 723–731, 1981.Google Scholar
  470. 470.
    Subramanian C, Yu S, McKhann CF: Soluble suppressor factor from the spleens of tumor-bearing mice. Cancer Res 38: 1996–2002, 1978.PubMedGoogle Scholar
  471. 471.
    Bertschmann M, Schären B, Löscher EF: Suppressor T cells and the regression phase of syngeneic intradermally developing P-815 mastocytomas. Eur J Cancer Clin Oncol 18: 405–411, 1982.PubMedGoogle Scholar
  472. 472.
    Minami A, Mizushima Y, Takeichi N, Hosokawa M, Kobayashi H: Dissociation of anti-tumor immune responses in rats immunized with solubilized tumor-associated antigens from a methylcholanthrene-induced fibrosarcoma. Int J Cancer 23: 358–365, 1979.PubMedGoogle Scholar
  473. 473.
    Minami A, Kasai M, Mizushima Y, Takeichi N, Hosokawa M, Kobayashi H: Characterization of immunosuppressive cells in rats immunized with solubilized tumor-associated antigens prepared from a methylcholanthrene-induced fibrosarcoma. Cancer Res 40: 2129–2134, 1980.PubMedGoogle Scholar
  474. 474.
    Morikawa K, Hosokawa M, Hamada J, Sugawara M, Kobayashi H: Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on rat fibrosarcoma. Cancer Res 45: 1502–1506, 1985.PubMedGoogle Scholar
  475. 475.
    Shearer GM, Melmon KL, Weinstein Y, Sela M: Regulation of antibody response by cells expressing histamine receptors. J Exp Med 136: 1302–1307, 1972.PubMedGoogle Scholar
  476. 476.
    Schechter B, Segal S, Feldman M: Generation of suppressor lymphocytes during sensitization in culture against a syngeneic tumor: Affinity chromatography on insolubilized histamine. J Immunol 120: 1268–1273, 1978.PubMedGoogle Scholar
  477. 477.
    Gifford RRM, Ferguson RM, Voss BV: Cimetidine reduction of tumour formation in mice. Lancet 1: 638–640, 1981.PubMedGoogle Scholar
  478. 478.
    Osband ME, Shen Y-J, Shlesinger M, Brown A, Hamilton D, Cohen E, Lavin P, McCaffrey R: Successful tumor immunotherapy with cimetidine in mice. Lancet 1: 636–638, 1981.PubMedGoogle Scholar
  479. 479.
    Schechter B, Feldman M: In vitro retrieval of the cytotoxic potential of spleen cells of tumor-bearing mice. Isr J Med Sci 14: 131–145, 1978.PubMedGoogle Scholar
  480. 480.
    Clerici E, Schechter B, Feldman M: Enrichment of suppressor cell activity by hydrocortisone: Suppression of in vitro activation of splenocytes from mice bearing Lewis lung carcinoma. Int J Cancer 25: 349–354, 1980.PubMedGoogle Scholar
  481. 481.
    Basten A, Miller JFAP, Johnson P: T-cell-dependent suppression of an anti-hapten antibody response. Transplant Rev 26: 130–169, 1975.PubMedGoogle Scholar
  482. 482.
    Gershon RK: T cell control of antibody production. Contemp Topics Immunobiol 3: 1–40, 1974.Google Scholar
  483. 483.
    Gershon RK, Lance EM, Kondo K: Immuno-regulatory role of spleen localizing thymocytes. J Immunol 112: 546–554, 1974.PubMedGoogle Scholar
  484. 484.
    Reinisch CL, Andrew SL: Regulation of cytotoxic T cell reactivity to syngeneic tumors by the thymus. J Exp Med 148: 619–623, 1978.PubMedGoogle Scholar
  485. 485.
    Ménard S, Colnaghi MI, Della Porta G: Natural anti-tumor serum reactivity in BALB/c mice. I. Characterization and interference with tumor growth. Int J Cancer 19: 267–274, 1977.PubMedGoogle Scholar
  486. 486.
    Colnaghi MI, Ménard S, Della Porta G: Natural anti-tumor serum reactivity in BALB/c mice. II. Control by regulator T cells. Int J Cancer 19: 275–280, 1977.PubMedGoogle Scholar
  487. 487.
    Takei F, Levy JG, Kilburn DG: Effect of adult thymectomy on tumor immunity in mice. Br J Cancer 37: 723–731, 1978.PubMedGoogle Scholar
  488. 488.
    Nordlund JJ, Gershon RK: Splenic regulation of the clinical appearance of small tumors. J Immunol 114: 1486–1490, 1975.PubMedGoogle Scholar
  489. 489.
    Gershon RK, Carter RL: Factors controlling concomitant immunity in tumor-bearing hamsters: Effects of prior splenectomy and tumor removal. J Natl Cancer Inst 43: 533–543, 1969.PubMedGoogle Scholar
  490. 490.
    Chang RWS, Turk JL: Increased resistance in splenectomized mice to a methylcholanthrene-induced tumor. Br J Cancer 35: 768–776, 1977.PubMedGoogle Scholar
  491. 491.
    Glaser M: Augmentation of specific immune response against syngeneic SV40induced tumor-associated antigens by splenectomy. Cell Immunol 45: 230–236, 1979.PubMedGoogle Scholar
  492. 492.
    Enker WE, Jacobitz JL: In vivo splenic irradiation eradicates suppressor T cells causing the regression and inhibition of established tumor. Int J Cancer 25: 819–825, 1980.PubMedGoogle Scholar
  493. 493.
    Berczi I, Sehon AH: Effector and suppressor lymphoid cells in tumor-bearing guinea-pigs. Int J Cancer 23: 274–282, 1979.PubMedGoogle Scholar
  494. 494.
    Lala PK, McKenzie IFC: An analysis of T lymphocyte subsets in tumour-transplanted mice on the basis of Lyt antigenic markers and functions. Immunology 47: 663–677, 1982.PubMedGoogle Scholar
  495. 495.
    Buessow SC, Paul RD, Miller AM, Lopez DM: Lymphoreticular cells isolated by centrifugal elutriation from a mammary adenocarcinoma. I. Characterization of an in situ lymphocyte suppressor population by surface markers and functional reactivity. Int J Cancer 33: 79–85, 1984.PubMedGoogle Scholar
  496. 496.
    Jessup JM, Cohen MH: Effects of murine tumors upon delayed hypersensitivity to dinitrochlorobenzene. II. Transitory delayed hypersensitivity in tumor-bearing mice. J Natl Cancer Inst 59: 1221–1226, 1977.PubMedGoogle Scholar
  497. 497.
    Indrová M, Bubeník J: Inhibition of cell mediated cytotoxicity against tumor-associated antigens by suppressor lymph node cells from mice bearing methylcholanthrene-induced sarcomas. Neoplasma 26: 405–412, 1979.PubMedGoogle Scholar
  498. 498.
    Indrová M, Bubeník J: Non T suppressor cells in the lymph nodes of mice bearing methylcholanthrene-induced sarcomas. Folia Biol 27: 217–222, 1981.Google Scholar
  499. 499.
    Fernbach BR, Kirchner H, Herberman RB: Inhibition of the mixed lymphocyte culture by peritoneal exudate cells. Cell Immunol 22: 399–403, 1976.PubMedGoogle Scholar
  500. 500.
    Hayami M, Hellström I, Hellström KE, Yamanouchi K: Cell-mediated destruction of Rous sarcomas in Japanese quails. Int J Cancer 10: 507–517, 1972.PubMedGoogle Scholar
  501. 501.
    Myburgh JA, Mitchison NA: Suppressor mechanisms in neonatally acquired tolerance to a Gross virus-induced lymphoma in rats. Transplantation 22: 236–244, 1976.PubMedGoogle Scholar
  502. 502.
    Gillette RW, Bonne CW: Changes in the mitogen response of lymphoid cells with progressive tumor growth. Cancer Res 35: 3774–3779, 1975.PubMedGoogle Scholar
  503. 503.
    Hanna N, Kripke ML: Immunologic significance of non-specific suppressor cells in spleens of tumor-bearing mice. Cell Immunol 43: 293–303, 1979.PubMedGoogle Scholar
  504. 504.
    Parthenais E, Haskill S: Specific T cell reactivity in mice bearing autochthonous tumors or early-generation transplanted spontaneous mammary tumors. J Natl Cancer Inst 62: 1569–1574, 1979.PubMedGoogle Scholar
  505. 505.
    Padarathsingh ML, McCoy JL, Dean JH, Lewis DD, Northing JW, Law LW: Examination of general and tumor-specific cell-mediated immune responses in mice bearing progressively growing plasmacytomas. J Natl Cancer Inst 58: 1701–1707, 1977.PubMedGoogle Scholar
  506. 506.
    Radov LA, Haskill JS, Korn JH, Fett JW: Correlation between tumor-specific systemic and in situ immunity as manifested by the delayed hypersensitivity response. J Natl Cancer Inst 62: 103–108, 1979.PubMedGoogle Scholar
  507. 507.
    Howell SB, Dean JH, Law LW: Defects in cell mediated immunity during growth of a syngeneic simian virus-induced tumor. Int J Cancer 15: 152–169, 1975.PubMedGoogle Scholar
  508. 508.
    Plata F: Enhancement of tumor growth correlates with suppression of the tumor-specific cytolytic T lymphocyte response in mice chronically infected by Trypanosoma cruzi. J Immunol 134: 1312–1319, 1985.Google Scholar
  509. 509.
    Roman JM, Golub ES: Leukemia in AKR mice. I. Effects of leukemic cells on antibody-forming potential of syngeneic and allogeneic normal cells. J Exp Med 143: 482–496, 1976.PubMedGoogle Scholar
  510. 510.
    Mulder AM, Durdik JM, Toth P, Golub ES: Leukemia in AKR mice. III. Size distribution of suppressor T cells in AKR leukemia and neonatal mice. Cell Immunol 40: 326–335, 1978.PubMedGoogle Scholar
  511. 511.
    Roman JM, Golub ES: Leukemia in AKR mice. II. Two modes of suppression of in vitro antibody formation by leukemic cells. Cell Immunol 40: 316–325, 1978.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1986

Authors and Affiliations

  • David Naor
  • Jonathan S. Duke-Cohan

There are no affiliations available

Personalised recommendations